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Breast cancer is the most common female cancer worldwide and yet, its aetiology is
unclear. It is believed that as a breast cancer lesion develops through progressive
stages from normal duct epithelium to atypical ductal hyperplasia, to DCIS and
invasive carcinoma, and finally to metastatic carcinoma, additional genetic alterations
occur in each successive stage. It is hypothesised that the p14ARF-hdm2-p53
regulatory pathway and E2F transcription factors play important roles in breast
carcinogenesis. Aberrations in p14ARF and hdm2 are biologically equivalent to
inactivation of p53. Alterations in E2Fs might abrogate the functions of p53, and E2F-
1-induced apoptosis occurs via p53-dependent and p53-independent pathways.
This study was conducted in four phases. The initial project investigated p53
mutations, p14ARF mutations and mRNA expression and hdm2 gene amplification in
invasive breast cancers and human breast cell lines. Having determined that p53
mutations were the most common aberrations, the second phase evaluated p53
expression by immunohistochemistry in invasive breast cancers in a series of Asian
women. The third project examined paired samples of DCIS and normal breast tissue
samples to identify the stage at which p53 mutations contribute to breast
carcinogenesis. Finally, mutational and expression analyses of E2F-1 and E2F-4 were
performed in primary breast cancers and matched samples of metastatic lymph nodal
tissues and normal breast tissues, and human breast cancer cell lines.
xi
p53 mutations were identified in 19% of the 36 primary breast cancers and 50% of the
14 breast cancer cell lines by SSCP analysis. p14ARF mutations and hdm2 gene
amplification absent and rare, respectively. The β transcript of p14ARF was expressed
in all tissue samples analysed by RT-PCR, suggesting that p14 activity could be
regulated by post-translational modification. Amplification of hdm2 was observed in
7% of the primary breast cancers.
Immunohistochemical analysis of p53 showed nuclear reactivity in 35% of the 105
cases. p53 immunopositivity correlated with poor histologic grade but not stage of
disease. Among these Asian women with a median follow-up of 5 years, patients with
p53 positive tumours experienced significantly shorter overall survival. However,
there was no significant difference in the disease-free survival.
For p53 mutational analysis in DCIS, 30 tissue samples representing specific
histologic subtypes of DCIS were obtained by tissue microdissection. p53 mutations
were detected in 20% of the DCIS lesions, but, absent in the corresponding normal
breast tissues. These findings support the hypothesis that p53 mutations are important
in the development of DCIS. There was no significant correlation between p53
mutational status and histologic subtype, nor between p53 mutations and nuclear
grade of the DCIS lesions.
Only polymorphisms were identified in both E2F-1 and E2F-4 among the human
tissue samples upon mutational analysis. One human breast cancer cell line harboured
xii
a missense mutation in E2F-1. Reduced expression level of both transcription factors
was observed in 70% of the 10 primary tumours compared to the corresponding
normal breast tissue, and in all the metastatic lymph nodal tissues. This marked
downregulation of the E2Fs in tumour tissues suggests a likely tumour suppressive
role in breast carcinogenesis and that they may be important in the development of
metastasis.
In conclusion, the results of the four studies show that p53 and the transcription
factors, E2F-1 and E2F-4, are likely to play significant roles in breast carcinogenesis.
The relatively frequent occurrence of p53 mutations in DCIS lesions and the absence
in normal breast tissues suggest that such aberrations are important in the
development of DCIS. Dysregulation of E2Fs appears to be more prevalent than that
of p53 mutations in breast carcinoma. E2F-1 and E2F-4 are likely to function as
tumour suppressors and the tumour suppressive property of E2F-1 could be attributed
to its ability to induce apoptosis. However, the function of downregulation of E2F-4
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Inactive adult mammary gland. A lobule comprises ductules (D) which are lined with
epithelial cells and are embedded in loose connective tissue (CT). (Magnification
X200)
Figure 2.
Invasive ductal carcinoma. The tumour cells are in solid sheets, exhibiting little
glandular pattern. There is marked nuclear pleomorphism with prominent nucleoli,
but, ocassional mitotic figures. (Magnification X200)
Figure 3.
Invasive lobular carcinoma. Tumour cells invade the stroma in single-file, resulting in
formation of linear strands. Cells are relatively uniform with little cytologic and
nuclear pleomorphism. (Magnification X 200)
Figure 4.
Comedo DCIS. Solid proliferation of tumour cells with prominent central necrosis
which is the hall mark of this histologic subtype. (Magnification X200)
Figure 5.
Solid DCIS. Tumour cells grow in a solid pattern without evidence of central
necrosis, fenestrations or papillations. (Magnification X100)
Figure 6.
Cribriform DCIS. Tumour cells grow in a fenestrated, sieve-like pattern.
(Magnification X200)
Figure 7.
Papillary DCIS. Tumour cells form finger-like projections that contain fibrovascular
cores. (Magnification X 150)
Figure 8.
Micropapillary DCIS. Tumour cells form small tufts that project into the lumen of the
involved space. These tufts lack fibrovascular cores. (Magnification X100)
Figure 9.
Schematic representation of the cell cycle, showing the role of p53 at the G1/S
checkpoint.
Figure 10.
Schematic representation of the p14ARF-hdm2-p53 regulatory pathway. The binding of
p53 to hdm2 results in inactivation and degradation of p53. When p53-dependent
cellular responses are required, p14ARF binds to hdm2 and targets hdm2 for
degradation. This in turn leads to stabilisation of the p53 protein.
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Figure 11.
Deregulation of the p14ARF-hdm2-p53 pathway and/or the E2F transcription factors
may be critical in breast carcinogenesis.
Figure 12.
SSCP analysis of p53 exon 8 in primary breast carcinomas. The tumour sample 53T
demonstrated mobility shift (marked with an asterisk).
Figure 13.
Sequence of p53 exon 8 in Case 53T. Missense mutation (CGT Æ CAT, Arg Æ His)
at codon 273 resulting from a substitution of a single nucleotide was identified. The
mutated nucleotide (G Æ A) is indicated by an arrow.
Figure 14.
Sequence analysis of p53 exon 6 in Case 4T. A polymorphism comprising a single
nucleotide substitution (CGA Æ CGG, Arg Æ Arg) at codon 213 was identified
(indicated by an arrow).
Figure 15.
Detection of hdm2 gene amplification by differential PCR in primary breast
carcinomas using phenylalanine hydroxylase (PAH) as the reference gene. The cell
line JAR representing 4-fold hdm2 gene amplification served as a positive control
while placental DNA and normal breast tissue (30N) served as negative controls.
Two-fold increase in hdm2 gene amplification was detected in Cases 17T and 36T
(marked with asterisks). Negative, a water blank was included in every gel to ensure
absence of contamination.
Figure 16.
SSCP analysis of p14ARF exon 1β in primary invasive breast carcinomas. No band
shift was detected. Negative, water blank to ensure the absence of contamination.
Figure 17.
Analysis of p14ARF expression by RT-PCR in primary invasive breast carcinomas. The
total RNA was reverse transcribed with (+) and without (−) reverse transcriptase for
each sample. Amplification of β-actin was used to demonstrate RNA integrity. The β
transcript was detected in all samples.
Figure 18.
Detection of hdm2 gene amplification by differential PCR in human breast cell lines,
using phenylalanine hydroxylase (PAH) as the reference gene. The cell line JAR
representing 4-fold hdm2 gene dosage served as a positive control while placental
DNA and normal breast tissue (30N) served as negative controls. Negative, a water
blank was included in every gel to ensure the absence of contamination. None of the
cell lines showed amplification of the gene.
xvii
Figure 19.
SSCP analysis of p14ARF exon 1β in human breast cell lines. MDA-MB-231 contained
a deletion of exon 1β (indicated by an arrow).
Figure 20.
Analysis of p14ARF expression by RT-PCR in breast cell lines. The total RNA was
reverse transcribed with (+) and without (−) reverse transcriptase for each sample.
Amplification of β-actin was used to demonstrate RNA integrity. The β transcript was
not detectable in MDA-MB-231.
Figure 21.
Intensity of nuclear immunostaining of p53 in invasive ductal carcinoma. (A)
Negative staining. (B) Weak immunoreactivity. (C) Moderately positive p53 staining.
(D) Strong immunopositivity. (Magnification x400)
Figure 22.
Overall survival of patients with invasive breast carcinoma according to p53 reactivity
using immunohistochemistry.
Figure 23.
Disease-free survival analysis of patients with invasive breast carcinoma according to
p53 reactivity using immunohistochemistry.
Figure 24.
Comedo-type DCIS characterised by a solid proliferation of large, pleomorphic
tumour cells (T) with prominent nucleoli and brisk mitotic activity, and central
necrosis (C). (Magnification x200)
Figure 25.
Non-comedo or low nuclear grade DCIS growing in a cribriform pattern. The
malignant cells exhibit a monomorphic appearance. Nucleoli show occasional
nucleoli and mitotic figures. (Magnification x400)
Figure 26.
Mutational analysis of p53 exon 6 in paired samples of DCIS and normal breast tissue
by SSCP. The papillary DCIS sample marked by an arrow demonstrated a mobility
shift. 4T is a breast carcinoma known to contain the polymorphism CGAÆCGG
(ArgÆArg) at codon 213. Paired samples are indicated by a horizontal line. Negative,
water blank.
Figure 27.
Mutational analysis of p53 exon 7 in paired samples of DCIS and normal breast tissue
by SSCP. Separate foci of comedo and cribriform subtypes were microdissected from
Case 7. The cribriform sample (indicated by an arrow) demonstrated a variant band
pattern similar to that of 34T, a breast carcinoma sample known to contain a point
xviii
mutation (CGGÆTGG; ArgÆTrp) in exon 7. Paired samples are indicated by a
horizontal line. Negative, water blank.
Figure 28.
SSCP analysis of E2F-1 exon 5 of matched normal breast tissues (N), primary breast
carcinomas (T) and metastatic lymph nodal tissues (L). All tissue types of Case 72
showed similar mobility shifts.
Figure 29.
Sequence analysis of E2F-1 exon 5 of the normal breast tissue (N), primary breast
carcinoma (T) and metastatic lymph nodal tissue (L) of Case 72. The polymorphism
comprising a single nucleotide substitution (ACGÆACA; ThrÆThr) (indicated by an
arrow) at codon 247 was identified in all tissue types.
Figure 30A and B.
SSCP analysis of E2F-4 polyserine tract of matched normal breast tissues (N),
primary breast carcinomas (T) and metastatic lymph nodal tissues (L). All tissue types
of Cases 23, 131 and 164 showed mobility shifts.
Figure 31.
Sequence analysis of E2F-4 polyserine tract of the matched normal breast tissue (N),
primary breast carcinoma (T) and metastatic lymph nodal tissue (L) of Case 23. The
addition of an AGC repeat (as indicated) was identified in all tissue types.
Figure 32A and B.
SSCP analysis of the pRb binding domain of E2F-4 in matched normal breast tissues
(N), primary breast carcinomas (T) and metastatic lymph nodal tissues (L). No
mobility shift was observed.
Figure 33.
Mutational analysis of E2F-1 exon 2 by SSCP. The breast cancer cell line BT-549
demonstrated a mobility shift which was not observed in the tissue samples. HEL is a
leukaemia cell line containing wild-type E2F-1. Matched tissue samples are indicated
by a horizontal line [normal breast tissue (N), primary breast carcinoma (T) and
metastatic lymph nodal tissue (L)].
Figure 34.
Sequence analysis of E2F-1 exon 2 in the breast cancer cell line BT-549. BT-549
contained a G:A transition (GCCÆACC;  AlaÆThr) at codon 102. The mutated
nucleotide (GÆA) is indicated by an arrow. HEL is a leukaemia cell line representing
the wild-type sequence.
Figure 35.
SSCP analysis of the pRb binding domain of E2F-4 in human breast cancer cell lines.
No mobility shift was observed.
xix
Figure 36A and B
Western blot analysis of E2F-1 expression in matched samples of normal breast
tissues (N), primary breast carcinomas (T) and metastatic lymph nodal tissues (L). (A)
Compared to the corresponding normal tissue, the expression of E2F-1 was higher in
the primary tumour but reduced in the metastatic nodal tissue of Case 29. (B) In Case
135, the expression level in the primary tumour was similar to that of the
corresponding normal tissue but reduced in the metastatic nodal tissue. In all other
cases, the expression of E2F-1 was lower in both the primary and metastatic tissues.
Figure 37A and B
Western blot analysis of E2F-4 expression in matched samples of normal breast
tissues (N), primary breast carcinomas (T) and metastatic lymph nodal tissues (L). In
Case 29, the expression of E2F-4 was higher in the primary tumour but lower in the
metastatic nodal tissue, compared to the corresponding normal tissue. In all other
cases, the expression level was lower in both the primary and metastatic tissues.
Figure 38A and B.
Expression of E2F-1 in breast cancer cell lines by western blot analysis.  The
leukaemia cell lines HEL and U937 represent high and low levels of protein
expression respectively (23). (A) BT-474, Hs 578T and SK-BR-3 expressed low
levels of E2F-1 while BT-549 expressed a moderate amount of the protein and ZR-
75-1 had a high expression level similar to that of HEL. (B) MCF7, MDA-MB-435
and MDA-MB-453 expressed high levels of E2F-1 while moderate level of
expression was observed in MDA-MB-436 and MDA-MB-468.
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1.1 EPIDEMIOLOGY AND INCIDENCE OF BREAST CANCER IN
SINGAPORE
Breast cancer in the most common malignancy affecting women in Singapore today
(Chia et al., 2000). The annual age-standardised mortality rate for breast cancer is
13.7 per 100,000 per year. It accounts for 22.8% of all female cancers with an
incidence of 46.1 per 100,000 per annum (age-standardised). The incidence has been
increasing steadily at 3.7% per year and has more than doubled over the last 30 years
(Table 1).
Table 1.  Age-Standardised Rates of the 10 Most Frequent Cancers Among Females
in Singapore Over the Last 30 Yearsa
Site 1968-72 1973-77 1978-82 1983-87 1988-92 1993-97
Breast 19.9 22.1 26.8 31.0 38.7 46.1
Colo-rectum 15.6 20.1 25.1 26.2 28.5 29.4
Lung 16.1 18.6 20.9 20.3 17.8 17.9
Cervix 18.1 17.5 16.6 16.1 15.2 14.2
Stomach 17.4 16.6 14.6 14.4 12.5 11.3
Ovary 6.0 6.3 8.6 8.8 10.5 11.4
Skin - 5.8 7.7 7.1 8.2 8.1
Corpus uteri - - - - 6.7 8.2
Thyroid - - 4.1 5.8 5.9 5.7
Nasopharynx 6.1 6.4 6.6 6.2 6.2 4.7
a Numbers are age-standardised rates per 100,000 per annum. (Modified from Chia et




This steady increase in incidence has been attributed to changes in lifestyle,
increasing affluence and an increase in the proportion of women in the industrial
workforce in Singapore. These changes in turn affect breast cancer risk factors such as
age at menarche, fertility and nutritional status. All these changes are likely to have
resulted in an alteration of the risk factor profile among our local women, such that it
is becoming similar to that of Caucasian populations (Willett et al., 2000). While the
incidence of breast cancer in Singapore is about a third of that in United States, and
half of that in Europe, the rate is higher than those in most countries in Asia such as
Japan, China, Hong Kong and India (Chia et al., 2000).
In Singapore, the median age of women affected with breast cancer is 50 years;
approximately 10 years younger when compared with women in the United Kingdom
and Untied States. The incidence peaks at the pre-menopausal age group of 45-49
years with more substantial annual increases observed in the pre-menopausal women
when compared to post-menopausal women (5.7% vs 3.9%) (Seow et al, 1996).
Albeit the local community is multi-racial (77.7% Chinese, 14.1% Malays, 7.1%
Indians and 1.0% others), breast cancer is the most frequent cancer among women of




1.2 HISTOPATHOLOGY OF BREAST CANCER
1.2.1 The Normal Breast
The adult breast is composed of 15 to 20 lobes of branched tubuloalveolar glands. The
lobes are further subdivided into lobules. The interlobular spaces comprise connective
tissue and adipose tissue. Each lobe is composed of a complex branching structure,
which can be divided into two components: the large ducts and the terminal duct-
lobular unit (TDLU). The large duct system consists of the subsegmental, segmental
and collecting or lactiferous ducts that converge and open onto the nipple. The TDLU
is connected to the subsegmental ducts and represents the secretory unit of the gland.
It is thought to be the site of origin of most pathologic entities of the breast, such as
fibrocystic changes, ductal hyperplasia and the majority of carcinomas, including both
the ductal and lobular types (Wellings et al., 1975; Faverly et al., 1994).
The lactiferous ducts are lined with stratified squamous epithelium, which gradually
changes to two layers of cuboidal cells and becomes a single layer of columnar or
cuboidal cells through the remainder of the duct system. These epithelial cells are
attached to an underlying basement membrane. In the inactive or resting mammary
gland, the secretory portion consists mainly of ductal elements embedded in loose
connective tissue (Figure 1). During pregnancy, the ductules branch and alveoli form,
in preparation for milk production. Between the epithelium and basement membrane




These cells contract and eject milk from the glands during lactation. During
menopause, the gland atrophies. The alveoli generate and disappear while some ducts
remain. Degenerative changes also occur in the connective tissue resulting in
reduction in stromal cells and collagen fibres.
Fig 1.  Inactive adult mammary gland. A lobule comprises ductules (D) which are







1.2.2 Primary Invasive Breast Carcinoma
The majority of malignant lesions arise in the TDLU of the breast. However, invasive
breast cancers constitute a heterogeneous group of tumours that differ with regard to
their clinical presentation, pathologic characteristics and biological behaviour.
Nevertheless, common to all, is the breach of the basement membrane of the duct with
the potential to invade the breast stroma and surrounding structures, as well as, the
potential for distant metastasis. The histologic classification of invasive breast
carcinoma is based on the growth pattern and cytologic features of the tumour. There
are two main groups: the special types (invasive breast cancers with specific or
special histologic features) and the invasive ductal carcinoma which is defined as a
type of cancer “not classified into any of the other categories”. Other terms for the
latter type include infiltrating ductal carcinoma, not otherwise specified (NOS)(Fisher
et al., 1975) and infiltrating carcinoma of no special type (NST)(Page and Anderson,
1987). The special types include lobular, tubular, medullary and mucinous carcinomas
and other rare types. At least 90% of the tumour should contain the defining
histologic characteristics for it to qualify as a special type cancer. The special type
cancers account for 20 to 30% of all invasive breast cancers, the most frequent being
invasive lobular carcinoma. The invasive or infiltrating ductal carcinomas constitute
the majority of breast cancers diagnosed.
The microscopic appearance of invasive ductal carcinoma is highly heterogeneous




may be arranged in glandular structures, as nests, cords or trabeculae, or as solid
sheets. Cytologically, cells may range from being very similar to normal breast
epithelial cells to showing marked cellular pleomorphism and nuclear atypia.
Likewise, mitotic activity may range from minimal to marked (Figure 2).
Fig 2.  Invasive ductal carcinoma. The tumour cells are in solid sheets, exhibiting
little glandular pattern. There is marked nuclear pleomorphism with prominent




Invasive lobular carcinoma, on the contrary, has distinctive cytologic features and
growth pattern. Tumour cells are characteristically small and relatively uniform, and
invade the stroma in single-file pattern. The nuclei are also small and show little
variation in size, with infrequent mitotic activity (Figure 3).
Fig 3.  Invasive lobular carcinoma. Tumour cells invade the stroma in single-file,
resulting in formation of linear strands. Cells are relatively uniform with little




In Singapore, the distribution of the histologic types is similar to that described in the
literature and is shown in Table 2.
Table 2.  Distribution of Histologic Types of Invasive Breast Carcinoma in
Singaporea
Histologic Type Proportion (%)








a Data from Chia et al., 2000.
b Includes comedocarcinoma, squamous cell carcinoma, malignant phylloides tumour,
sarcoma of the breast, etc.
1.2.3 Ductal Carcinoma In Situ (DCIS)
Ductal carcinoma in situ (DCIS) or intraductal carcinoma is a primary malignant
neoplasm of the breast that is confined to the ducts without evidence of invasion into
the mammary stroma. It is believed to be the preinvasive form of ductal carcinoma.
Similar to invasive disease, the term DCIS comprises a heterogeneous group of




and non-comedo types. The non-comedo type encompasses several architectural
variants including solid, cribriform, micropapillary/clinging and papillary. (Page and
Rogers, 1987; Rosai, 1996). More recent proposed classification schemes of DCIS
take into account the nuclear grade of the lesions. (Holland et al., 1994; Silverstein et
al., 1995). Truly, DCIS represents a spectrum of ductal proliferations with at one end
of the spectrum the high grade lesions in which microinvasive foci may be present
and, the other end of the spectrum is represented by low grade DCIS that may be
difficult to distinguish from atypical ductal hyperplasia. In addition, DCIS lesions are
also morphologically heterogeneous. Often, a combination of different histologic
subtypes exists within a single tumour.
Comedo type DCIS is composed of a solid proliferation of large and pleomorphic
epithelial cell within ducts, usually exhibiting numerous mitoses and central necrosis
containing cellular debris (so-called “comedo-necrosis”). The necrotic material often
becomes calcified and these calcifications have a distinctive mammographic
appearance. The stroma around the involved ducts classically shows concentric
fibrosis and chronic inflammation. Microinvasion is a feature more commonly





Fig 4.  Comedo DCIS. Solid proliferation of tumour cells with prominent central




The tumour cells in non-comedo DCIS are uniformly small to medium in size with
hyperchromatic nuclei. Nucleoli and necrosis are usually not present and mitoses are
only occasionally seen. Microcalcifications may be associated with these non-comedo
subtypes and may be detected by mammography. In solid DCIS, the tumour cells fill
and distend the involved ducts, but, without central necrosis (Figure 5). 
Fig 5.  Solid DCIS. Tumour cells grow in a solid pattern without evidence of central




The cribriform variant is characterised by a fenestrated, sieve-like proliferation of
tumour cells (Figure 6). 
Fig 6.  Cribriform DCIS. Tumour cells grow in a fenestrated, sieve-like pattern.
(Magnification X 200)
Papillary DCIS demonstrates intraluminal projections of tumour cells that contain
fibrovascular cores. The cells are oriented perpendicular to the basement membrane of
the involved duct. The micropapillary subtype differs from the papillary DCIS in that




Fig 7.  Papillary DCIS. Tumour cells form finger-like projections that contain
fibrovascular cores. (Magnification X150)
Fig 8.  Micropapillary DCIS. Tumour cells form small tufts that project into the lumen




1.3 CLINICAL PRESENTATION, STAGING AND TREATMENT OF
BREAST CANCER
Women with breast cancer may present in a number of ways. The most common
presentation is that of a self-detected lump or mass in the breast. Other symptoms
include skin retraction or ulceration, changes of the nipple such as retraction,
discharge and eczema, breast pain, a lump in the axilla, and symptoms from
metastatic disease such as bone pain and dyspnoea. In asymptomatic patients, occult
breast cancer can be detected by mammography and/or breast ultrasound examination.
Such imaging modalities are capable of detecting the presence of the pre-invasive
form, i.e., DCIS. In North America and many European countries where screening
mammography has been widely employed for many years, DCIS accounts for up to
30% of all breast cancers. However, in Singapore, BreastScreen Singapore, the
national breast cancer screening programme was launched only in January 2002. As
such, DCIS constitutes less than 5% of all breast cancers diagnosed in this country
prior to screening programme.
Breast cancer is staged according to the American Joint Committee on Cancer (AJCC)
TNM Staging System (Appendix 1), in which T represents the tumour size, N the
axillary nodal status and M the presence or absence of distant metastasis. DCIS
lesions without evidence of invasive disease, and regional and distant metastasis are




comprises locally advanced disease. The presence of distant metastasis represents
Stage IV disease.
While the management of breast cancer involves a multimodality approach, surgery is
the cornerstone in the treatment of Stages I to III disease, with chemotherapy,
hormonal therapy and radiotherapy fulfilling an adjuvant role. The combination
therapy selected is dependent on several factors, such as the size of the primary
tumour, the number of axillary lymph nodes involved, the presence/absence of
lymphovascular invasion, the patient’s age and the presence/absence of co-morbid
medical conditions. In general, early breast cancer and operable Stage III tumours are
treated by surgery followed by adjuvant chemotherapy and/or radiotherapy.
Inoperable locally advanced breast cancer would require preoperative chemotherapy
to downsize the tumour before surgical extirpation, followed by radiotherapy. In all
cases, hormonal therapy with Tamoxifen is used when the tumour demonstrates
presence of oestrogen and/or progesterone receptors (ER/PR). The aims of treatment
of Stage IV disease are mainly to palliate symptoms in order to improve the quality of
life and to prolong survival. Chemotherapy and hormonal therapy are the mainstay of
treatment while radiotherapy is used to minimise pain from bony metastases or
complications from brain secondaries. At this stage, surgery in the form of toilet
mastectomy is considered when a fungating or ulcerated tumour is present.
Prognosis from breast cancer is dependent on the stage of disease at presentation.




Stage I and II patients have an approximate 5-year survival of 90% and 70%
respectively. The survival for Stage III disease is about 40% at 5 years, while that for
patients with metastatic disease is a dismal 10%.
1.4 PATHOGENESIS OF BREAST CANCER
1.4.1 The Breast Carcinogenesis Model
Cancer, for the most part, is caused by somatic mutations, with each individual cancer
arising from an accumulation of genetic alterations, rather than a single mutation. This
“multi-hit” model was first hypothesised by Foulds in 1958 (Foulds, 1958) and later
re-visited by Knudson who proposed the classical two-hit model (1971). However, it
was only recently that this “multi-hit” model was supported at the molecular level.
Vogelstein and others have best defined this model in colorectal carcinogenesis
(Vogelstein, 1988; Fearon and Vogelstein, 1990). It has been demonstrated that each
step in the progression from normal epithelium to metastatic carcinoma (normal
epithelium Æ hyperproliferative epithelium Æ early adenoma Æ intermediate
adenoma Æ late adenoma Æ carcinoma Æ metastasis) is accompanied by additional
genetic alterations.
It is believed that breast cancer, similar to colorectal cancer, develops through




normal duct epithelium Æ ductal hyperplasia Æ atypia Æ DCIS Æ invasive ductal
carcinoma Æ metastatic carcinoma. Thus, additional genetic alterations must occur in
the successive stages of breast cancer development and progression. While there is
some evidence to support certain parts of this model, it has been difficult to study
each individual stage of breast carcinogenesis because of the heterogeneous nature of
most breast tumours. Unlike the colorectal model in which distinct, well defined
morphologic stages are available for molecular analysis, in breast tissue, samples
representing different single histologic stages from the same tumour are difficult to
obtain and there is substantial stromal contamination in any tumour.
1.4.2 Genetic Basis of Breast Carcinogenesis
The genetics of carcinogenesis involve both oncogenes and tumour suppressor genes,
many of which participate in regulatory pathways involved in cell cycle regulation
and programmed cell death (apoptosis). Uncontrolled cellular proliferation is the
hallmark of cancer. As such, cell cycle regulation is a key target of oncogenic
processes. The introduction of errors into the genes that control the cell cycle can
result in failure of the mechanisms, which govern the entry into and exit from the cell
cycle. This in turn results in the potential to proliferate in an uncontrolled manner and
ultimately tumour development. Several oncogenes and tumour suppressor genes have
been identified and characterised to date, reflecting the complex nature of normal and




participate in all or even most human cancers, the high frequency of alterations in the
tumour suppressor gene p53 in human malignancies suggests that the gene plays a
central role in the carcinogenesis of different tumours. In fact, p53 is reportedly the
most common genetic target in breast cancer (Elledge and Allred, 1994). Other
commonly involved genes in breast cancer include oncogenes such as c-myc, c-erb-B2
and cyclin D1 (CCND1) and tumour suppressor genes such as the retinoblastoma
susceptibility gene Rb and p16INK4A (Dickson and Lippman, 2000). 
1.4.3 The Cell Cycle
The cell cycle comprises a complex chain of events which results in the replication of
genetic material of a cell and the segregation of the two copies of genetic material into
two daughter cells. The cell cycle is described in four phases: G0, a quiescent non-
cycling state; G1, the preparation for DNA synthesis; S, DNA synthesis; G2, the
preparation for nuclear and cell division; M, mitosis. There are two major control
points within the cell cycle: G1/S and G2/M checkpoints. At the G1/S checkpoint, a
critical decision on whether to proceed with cell division or to enter an alternative
developmental state such as differentiation is made. Once the decision to divide is
made, the cells are committed to exit from G1 and enter the S phase of the cell cycle.
At the G2/M checkpoint, a second decision is necessary before the onset of mitosis.




for segregation at mitosis. If there is DNA damage, cells are able to arrest to allow
repair of the defective DNA. 
All the processes in the cell cycle are highly regulated by a series of proteins known
as cyclin-dependent kinases (CDKs), their activating subunits, the cyclins, and their
inhibitory subunits, the CDK inhibitors (CDKIs). These CDK complexes interact with
signalling pathways and act at different phases of the cell cycle to co-ordinate cell
cycle progression. At the G1/S checkpoint, the G1 cyclins mediate G1 to S phase; the
cyclin D-CDK4 complex regulates progression through G1 while the cyclin E-CDK2
complex mediates the transition from G1 to S phase. The cyclin D-CDK4 complex is
inhibited by specific CDKIs such as p16INK4A, p15INK4B, p21 (Waf-1/CIP1) and p27
(Kip-1) while Cyclin E-CDK2 complex is inhibited by p21 (Waf-1/CIP1) and p27
(Kip-1). p21 (Waf-1/CIP1) is regulated by the tumour suppressor p53.
1.5 THE TUMOUR SUPPRESSOR p53
1.5.1 Functions of p53
The p53 gene is located on chromosome 17p13.1 (Isobe et al., 1986; McBride et al.,
1986) and encodes a 53kDa nuclear phosphoprotein comprising 393 residues. The
protein has four highly conserved domains: the N-terminal transactivation, central




each domain has distinct and independent functions, alterations within one domain
can influence the functions of other domains (Hupp, 1999). Having a DNA binding
domain, which interacts with genomic DNA in a sequence-specific manner, qualifies
p53 as a transcription factor. It can promote or repress the expression of target genes
containing p53 binding sites, such as, p21 (Waf-1/CIPI) and hdm2 (Levine, 1997).
Nuclear localisation of p53 is necessary for its transcriptional function (Gannon and
Lane, 1991; Shaulsky et al., 1991), but its degradation selectively occurs in the
cytoplasm (Roth et al., 1998).
p53 is involved in many functions at the cellular level, including regulation of normal
cell growth and division, DNA repair and genomic stability (Haffner and Oren, 1995).
As such, it is regarded as the guardian of the genome (Lane, 1992; Janus et al., 1999).
Several lines of evidence support its role as a tumour suppressor. Wild-type p53 could
inhibit the transformation of rodent cells and revert the malignant phenotype of
human cancer cells in vitro (Eliyahu et al., 1989; Finlay et al., 1989). Monoallelic loss
of variable portions of the short arm of chromosome 17 was observed in a variety of
human tumour types (Nigro et al., 1989) and this loss was consistently associated
with mutations of the residual p53 allele (Baker et al., 1989; Nigro et al., 1989;
Takahashi et al., 1989). In addition, majority of p53 mutations found in human





1.5.2 The Role of p53 at the G1/S Checkpoint of the Cell Cycle
p53 plays a crucial role in the control of this checkpoint. It can induce cell cycle arrest
and apoptosis in response to DNA damage and oncogenic signals in order to maintain
genetic integrity (Reviewed in Asschert et al., 1998). Although the exact mechanisms
by which p53 controls the fate of cells are not fully understood, several steps at this
checkpoint have been elucidated (Figure 9). 






















In the G1 phase, DNA damage induces upregulation of p53 protein in the cell by
stabilisation of the protein (Epstein, 1990; Kastan et al., 1991; Donehower and
Bradley, 1993; Fritsche et al., 1993; Nelson and Kastan, 1994). It acts as a
transcription factor and transactivates several genes amongst which are p21 (El-Deiry
et al., 1993), Bax (which induces apoptosis)(Miyashita and Reed, 1995) and GADD45
(which functions in DNA repair)(Kastan et al., 1992). p21 in turn inhibits the function
of Cyclin D-CDK4 and Cyclin E-CDK2 complexes (El-Deiry et al., 1994; Harper et
al., 1995), leading to an accumulation of hypophosphorylated retinoblastoma gene
product pRb. The hypophosphorylated pRb binds to and abrogates the activity of E2F,
transcription factors that are required for entry into S phase (Dyson, 1998). Thus,
when DNA damage is encountered, p53 induces G1 arrest to allow the cell to repair
the DNA. Once the DNA errors are corrected, p53 activates hdm2, which in turn
binds to and inactivates p53, preventing prolongation of G1 arrest (Momand et al.,
1992; Wu et al., 1993; Chen et al., 1994). If the DNA damage is irreparable, the cell
may be driven down the apoptotic pathway in order to prevent the replication of
defective cells (Gottlieb and Oren, 1996).
1.5.3 Inactivation of p53
Mutated p53 proteins cannot bind to DNA-specific sequences (Milner and Medcalf,
1991) and thereby, are unable to activate transcription of genes responsive to the wild-




form can form complexes with wild-type p53 preventing its interaction with DNA
(Milner and Medcalf, 1991). Thus, the loss of p53 function eliminates the growth
arrest and apoptotic responses to DNA damage (Kastan et al., 1992) and results in
uncontrolled cell proliferation. Various mechanisms of p53 inactivation have been
identified, which include homozygous deletions, rearrangements, loss of
heterozygosity or point mutations (Baker et al., 1989; Nigro et al., 1989; Takahashi et
al., 1989; Mulligan et al., 1990; Prosser et al., 1990). The p53 protein may also be
inactivated by binding to DNA tumour virus proteins such as SV40 large tumour
antigen (Lane and Crawford, 1979; Linzer and Levine, 1979), adenovirus E1B-55
kDa protein (Sarnow et al., 1982) and human papillomavirus E6 protein (Werness et
al., 1990), and cellular oncoproteins such as hdm2 (Momand et al., 1992; Oliner et
al., 1993) when the gene is intact. 
The level of wild-type p53 protein is very low in normal cells due to its short half-life
(Oren et al., 1981). The proteolytic turnover of wild-type p53 protein occurs with a
half-life of 6-20 min, depending on the cell type (Rogel et al., 1985). However, the
protein is stabilised and accumulates in cells that have sustained genotoxic damage.
Mutant p53 proteins that are activated for transformation have extended half-lives of
up to 2-12 hr, and are found in the transformed or tumour cells is higher
concentrations (Oren et al., 1981; Reich et al., 1983). Thus, recognition of p53 by
immunohistochemistry is thought to be due to the presence of the mutated form (Lane




1.5.4 Significance of p53 in Breast Carcinogenesis
It is believed that p53 is the most commonly altered gene in human breast cancer.
Genetic alterations in the form of p53 mutations have been identified in 14% to 46%
of invasive breast carcinomas (Osborne et al., 1991; Runnebaum et al., 1991; Elledge
et al., 1993; Bergh et al., 1995; Hartmann et al., 1995; Kovach et al., 1996; Cuny et
al., 2000), depending on the method of detection used and the regions of the gene
analysed. Similarly, the incidence of p53 positive breast carcinomas in
immunohistochemical studies ranges from 14% to 58%, depending on the fixation
method, the antibodies used for detection (different antibodies have varying
sensitivity and specificity), and the cut-off of percentage of stained nuclei considered
as positive staining (Isola et al, 1992; Thor et al., 1992; Friedrichs et al., 1993;
Hurlimann, 1993; Lipponen and Ji, 1993; Bhargava et al., 1994; Umekita et al.,
1994a; Beck et al., 1995; Haerslev et al., 1995; MacGrogan et al., 1995; Pietilainen et
al., 1995; Rosen et al., 1995; André et al., 1997). Neither homozygous deletions nor
rearrangements of the gene have been described in breast carcinomas (Chen et al.,
1991).
There are also data to suggest that p53 mutations may be important in the
development of DCIS (Done et al., 1998). p53 protein accumulation has been
identified in 13-40% of DCIS lesions (Davidoff et al., 1991a; Thor et al., 1992; Poller
et al., 1993; Bobrow et al., 1994; Eriksson et al., 1994; Zafrani et al., 1994; Bose et




reportedly more frequent in the comedo subtype (Bose et al., 1996; Moreno et al.,
1997; Rajan et al., 1997) and high grade DCIS (Bobrow et al., 1994; Zafrani et al.,
1994; Rajan et al., 1997). A recent study suggests that accumulation of p53 protein is
associated with increased risk of subsequent breast carcinoma in women with benign
breast disease (Rohan et al., 1998).
1.6 p14ARF-hdm2-p53 REGULATORY PATHWAY
1.6.1 hdm2
hdm2, the human homologue of the mdm2 (mouse double minute 2) gene, is an
oncogene located at chromosome 12q13-14 (Oliner et al., 1992). It encodes a 491
amino acid protein with a zinc-binding RING finger motif (Leng et al., 1995). In
transfection studies, amplification and overexpression of mdm2 conferred tumorigenic
potential to rodent fibroblasts, producing tumours in athymic mice when the
transfected fibroblasts were injected subcutaneously (Fakharzadeh et al., 1991).
Transfected rodent fibroblasts also overcame wild-type p53-mediated suppression of
cell proliferation (Finlay, 1993). Its role as an oncogene was further strengthened by
the observation of hdm2 gene amplification in a third of human soft tissue sarcomas




Hdm2 regulates several functions of p53, including growth suppression and apoptosis
(Chen et al., 1994; Chen et al., 1996; Haupt et al., 1996). The hdm2 protein binds to
p53 and inhibits p53-mediated transcriptional activity (Momand et al., 1992; Oliner et
al., 1993; Chen et al., 1996) by concealing the transactivation domain of p53 (Oliner
et al., 1993). Hdm2 also targets the p53 protein for rapid proteasomal degradation
(Haupt et al., 1997; Kubbutat et al., 1997). Interestingly, hdm2 is transcriptionally
induced by p53 (Barak et al., 1993; Wu et al., 1993). Hence, the p53 protein regulates
hdm2 at the level of transcription while the hdm2 protein regulates p53 at the level of
its activity. These activities form an autoregulatory feedback loop in which p53 limits
its own activity through the production of hdm2 (Wu et al., 1993). In a normal cell,
low levels of inactive p53 protein are maintained by hdm2 protein which binds to p53
in the nucleus and shuttles it to the cytoplasm for degradation by cytoplasmic
proteasomes (Roth et al., 1998; Tao and Levine, 1999a). In response to DNA damage,
this feedback loop is modulated such that p53 protein is stabilised to allow for
appropriate p53 responses. It is believed that this reciprocal regulation is necessary to
maintain controlled cell growth.
Besides soft tissue sarcomas, the amplification and/or overexpression of hdm2 has
also been identified in a myriad of other human malignancies such as carcinoma of
the breast (Marchetti et al., 1995a; McCann et al., 1995; Bueso-Ramos et al., 1996;
Courjal et al., 1996), oesophagus (Esteve et al., 1993; Shibagaki et al., 1995), lung
(Marchetti et al., 1995b; Gorgoulis et al., 1996; Higashiyama et al., 1997),




thyroid (Zou et al., 1995). In addition, alternative mechanisms of dysregulation of
hdm2 expression have been described, such as, increased mRNA levels in the absence
of gene amplification (Bueso-Ramos et al., 1993; Sheikh et al., 1993) and enhanced
translation without gene amplification or elevated levels of mRNA transcripts
(Landers et al., 1994).
The hdm2 gene has been shown to be abnormally upregulated in breast tumours by
gene amplification and overexpression (Marchetti et al., 1995a; McCann et al., 1995;
Courjal et al., 1996; Cuny et al., 2000), suggesting a possible role for hdm2
alterations in breast tumorigenesis. Bueso-Ramos et al. (1996) reported
overexpression of hdm2 mRNA and protein in 73% of human breast carcinomas in
the absence of hdm2 gene amplification.
1.6.2 p14ARF
p14ARF, an alternate transcript of the INK4A tumour suppressor locus, is the human
homologue of the murine p19ARF. The INK4A locus is situated at chromosome 9p21
and comprises exons 1α, 1β, 2and 3 (Kamb et al., 1994; Nobori et al., 1994). This
gene yields two transcripts, designated α and β transcripts, from different promoters.
The α transcript, comprising exons 1α, 2 and 3, encodes the CDKI p16INK4A, which
specifically inhibits the G1 CDKs (CDK4 and CDK6) (Sherr, 1996). The β transcript




(ARF) and encodes p14ARF (Mao et al., 1995; Quelle et al., 1995; Stone et al., 1995).
The amino acid sequences of these two proteins are completely different. The p14ARF
protein inhibits cell cycle progression by inducing G1 and G2/M phase arrest (Quelle
et al., 1995; Stott et al., 1998) and this function does not involve a direct interaction
with CDKs or cyclins (Quelle et al., 1995). This property appeared to be p53
dependent as p53-negative cell lines were resistant to p14ARF-induced growth arrest
(Stott et al., 1998; Kamijo et al., 1997). In addition, a lack of DNA damage-induced
arrest in p19ARF–deficient mouse embryo fibroblasts correlated with decreased basal
p53 levels and an inability to sustain induction of p53 (Khan et al., 2000). It has been
shown that the peptide encoded by exon 1β of INK4A alone (the N-terminal part of
p14ARF) is both necessary and sufficient for inducing cell cycle arrest and that neither
mutations nor complete deletion of exons 2 and 3 abrogated cell cycle inhibitory
function of p14ARF (Quelle et al., 1997). 
There are data to suggest that p14ARF is a tumour suppressor gene. Ablation of exon
1β in mice resulted in increased tumour development (Kamijo et al., 1997).
Embryonic fibroblasts of p19ARF-null mice grown in culture failed to undergo
senescence and become immortalised (Kamijo et al., 1997). To date, there is limited
evidence to implicate p14ARF in human malignancies. Homozygous deletions of
p14ARF have been reported in a variety of human cancer cell lines and in 19% of
primary non-small cell lung carcinomas (Nicholson et al., 2001). However, no exon




al., 1996) and those found in exon 2 are not deleterious for p14ARF activity (Quelle et
al., 1997). 
1.6.3 The p14ARF-hdm2-p53 Pathway
While overexpression of p19ARF in wild-type or p19ARF-null mouse embryo fibroblasts
increased the half-life of p53 (Kamijo et al., 1998), it was the elucidation of a direct
interaction between p14ARF and hdm2 that established a functional link between
p14ARF and p53 (Pomerantz et al., 1998; Stott et al., 1998; Zhang et al., 1998). It has
been shown that p14ARF co-localises and associates with hdm2 (Tao and Levine,
1999b; Weber et al., 1999). This interaction blocks the shuttling of hdm2 from the
nucleus to the cytoplasm, as well as, changes the subcellular localisation of hdm2
from the nucleoplasm to the nucleolus (Tao and Levine, 1999b). This in turn prevents
the export of p53 from the nucleus, thereby inhibiting p53 degradation (Kamijo et al.,
1998; Tao and Levine, 1999b). In addition, p14ARF binds to and promotes rapid
degradation of hdm2 (Zhang et al., 1998). Hence, the binding of p14ARF to hdm2
stabilises p53 and enhances p53-dependent transactivation and growth inhibition. The
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Fig 10.  Schematic representation of the p14ARF-hdm2-p53 regulatory pathway. The
binding of p53 to hdm2 results in inactivation and degradation of p53. When p53-
dependent cellular responses are required, p14ARF binds to hdm2 and targets hdm2 for




1.7 E2F TRANSCRIPTION FACTORS
The E2F family of transcription factors comprises six members, designated E2F-1 to
E2F-6 (Lam and La Thangue, 1994; Hijmans et al., 1995; Sardet et al., 1995;
Trimarchi et al., 1998), with the ability to regulate overlapping sets of target genes.
They are able to mediate both transcriptional activation and repression. These
transcription factors regulate the expression of a number of genes important in cell
proliferation, particularly those involved in the progression through G1 and S phase of
the cell cycle. An important role for the E2Fs in carcinogenesis is suggested by the
finding that in most human neoplasias, genetic or epigenetic alterations occur that
ultimately result in the deregulation of E2F-dependent transcription.
Each of the E2F proteins contains a related DNA binding and dimerization domain
and, all except E2F-6, also contain a transactivation domain. Each protein functions as
a heterodimer with a member of the DP family (DP1 and DP2), with the binding
specificity being conferred by the E2F subunit (reviewed in Dyson, 1998). E2F
activity is regulated by interaction with pRb or related family members (p107 and
p130), which are also known as pocket proteins. This interaction inactivates E2F in
two ways: 1) repression of E2F activity by masking the transactivation domain of
E2F, or, 2) conversion of E2F into an actively repressing complex by recruiting
histone deacetylases to inhibit gene expression at the promoter (Brehm et al., 1998;




and E2F-3 favour binding to pRB while E2F-4 binds with high affinity to p107 and
p130, and E2F-5 to p130 (Dyson, 1998).
E2F-1 is the most well characterised member. There is a wealth of data to support the
oncogenic potential of this transcription factor. Ectopic expression of E2F-1 promotes
cell cycle progression by driving quiescent cells through G1 into S phase overriding
growth inhibitory signals (Johnson et al., 1993). It also induces DNA synthesis and
cell proliferation (Johnson et al., 1993; Qin et al., 1994; Kowalik et al., 1995).
Mutational studies show that the ability of E2F-1 to drive cells into S phase requires
its DP-binding, DNA-binding and transactivation domains (Johnson et al., 1993; Qin
et al., 1994). It can also cooperate with the ras oncogene to induce neoplastic
transformation in vitro and in vivo (Johnson et al., 1994; Singh et al., 1994). Pierce et
al. (1998) further showed that transgenic mice which overexpressed E2F-1 in their
epidermis developed skin tumours. On the contrary, E2F-1 overexpression results in
apoptosis (Qin et al., 1994; Shan et al., 1994; Wu et al., 1994; Phillips, 1997). Mice
nullizygous for E2F-1 showed defects in apoptotic function and increased
tumorigenesis (Field et al., 1996; Yamasaki et al., 1996), while E2F-1 overexpression
in testis of transgenic mice resulted in testicular atrophy due to apoptosis (Holmberg,
1998). These findings suggest that E2F-1 has tumour suppressive properties.
Due to the seemingly diametrically opposite functions, E2F-1 may act as an oncogene
or a tumour suppressor, depending on the tissue type and/or experimental conditions.




reported that decreased expression of E2F-1 is associated with an increased risk of
progression to metastasis and death (Rabbani et al., 1999). However, amplification
and overexpression of E2F-1 was identified in 63% of gastric cancers, suggesting that
it may act as an oncogene in gastrointestinal carcinomas (Suzuki et al., 1999). 
Relatively less is known about E2F-4. It is the major species in quiescent cells (Ikeda
et al., 1996) and its mRNA expression is maximal in mid-G1 when E2F-1 is
undetectable (Sardet et al., 1995). It accounts for most of the endogenous E2F DNA-
binding activity during G1 (Ikeda et al., 1996; Moberg et al., 1996). E2F-4 has a
unique serine repeat domain that is not found in the other E2F members. Although the
function of this domain is unknown, it has been found to be a target of mutation in
replication error-positive colorectal cancers (Ikeda et al., 1998). Similar to E2F-1,
there are data to suggest that E2F-4 has oncogenic properties. It can drive cell cycle
progression (Beijersbergen et al., 1994) and cause transformation of mammalian
fibroblasts (Beijersbergen et al., 1994; Ginsberg et al., 1994). In a mouse skin two-
stage chemical carcinogenesis model, E2F-4 transgenic mice developed tumours
sooner and in greater numbers compared to non-transgenic mice (Wang et al., 2000).
Unlike E2F-1, an in vitro study suggested that E2F-4 does not induce apoptosis
(DeGregori et al., 1997). This was further supported by an in vivo study using E2F-4
transgenic mice (Wang et al., 2000).
E2F-1 can induce apoptosis via both p53-dependent (Wu and Levine, 1994; Qin et al.,




et al. (1997) showed that E2F-1 overexpression could induce apoptosis in breast
cancer cell lines with mutations in p53 or Rb. It has also been shown that
overexpression of E2F-1 enhanced apoptosis following treatment with DNA
damaging chemotherapeutic agents in various human cancer cell lines with mutant
p53 (Meng et al., 1999). Recent data suggest that E2F-1 induces apoptosis in the
absence of p53 by the transcription of p73, an evolutionary relative of p53 (Irwin et
al., 2000). Disruption of p73 inhibited E2F-1-induced apoptosis in p53 defective
tumour cells and in p53 null mouse embryo fibroblasts. 
Wu and Levine (1994) were the first investigators to demonstrate that E2F-1 induced
apoptosis was p53-dependent in some cell lines. Subsequently, it was reported that
E2F-1 overexpression resulted in induction of p53 (Hiebert et al., 1995; Kowalik et
al., 1998), and that both induction of apoptosis and accumulation of p53 could be
blocked by expression of hdm2 (Kowalik et al., 1998). The functional relationship
between E2F-1 and the p14ARF-hdm2-p53 pathway was revealed by the identification
of potential E2F binding sites in the ARF promoter and that the promoter was highly
responsive to E2F-1 expression (Robertson et al., 1998). In addition, p14ARF
expression can be transactivated by E2F-1 (Bates et al., 1998). More recently,
Itoshima et al. (2000) showed that E2F-1 overexpression directly activates expression
of p14ARF with resultant decreased hdm2 expression and stabilisation of p53 in human
oesophageal cancer cells. It has been suggested that the differential ability of E2F-1
and E2F-4 to induce apoptosis correlates with their differential ability to activate the





The hypothesis proposed in this thesis is that dysregulation of the p14ARF-hdm2-p53
regulatory pathway and the E2F transcription factors play important roles in breast
carcinogenesis. While p53 is the most commonly altered gene in human breast cancer,
more than 50% of breast cancers contain wild-type p53. A certain proportion of these
cancers might harbour genetic aberrations in p14ARF and hdm2, which are biologically
equivalent to inactivation of p53. Similarly, alterations in E2Fs at the genetic and/or
expression level might abrogate the functions of p53. Although it has not been
conclusively shown whether E2F-induced apoptosis is or is not dependent on p53 in
breast carcinoma, genetic or epigenetic alterations that ultimately result in the
deregulation of E2F-dependent transcription have been reported in many human
neoplasias, leading to the postulation that their dysregulation might be important in




Fig 11. Deregulation of the p14ARF-hdm2-p53 pathway and/or the E2F transcription
















1.9 SCOPE OF THE STUDY
The entire study was performed in four sections. The initial project analysed the
components of the p14ARF-hdm2-p53 pathway in invasive breast cancers. The most
commonly altered gene was subsequently investigated in the pre-invasive form of
breast cancer and normal breast tissues, in order to determine the stage at which the
genetic alterations play an important role. With recent reports showing interaction
between the E2F transcription factors and p14ARF, the final part of the study evaluated
the role of these transcription factors in breast carcinomas.
The four objectives are:
(1) Investigation of Genetic alterations in p14ARF-hdm2-p53 regulatory
pathway
Considering the mechanistic and functional relationship of the three genes, p14ARF,
hdm2 and p53, the presence of inactivating mutations in p14ARF, or hdm2
amplification may be biologically equivalent to inactivation of p53. The first project
investigated the components of this pathway at the genetic level in a series of primary





(2) Immunohistochemical analysis of p53 in primary breast carcinomas and
correlation with clinicopathological parameters
Having determined that p53 mutations were the most common aberrations whereas
p14ARF and hdm2 alterations were uncommon, subsequent work was focused on the
tumour suppressor p53. Immunohistochemical expression of p53 has been widely
used as a surrogate marker of underlying genetic alterations in p53. While there are
numerous reports on p53 expression in breast cancer among Caucasian populations,
there is very limited information on Asians. The second project evaluated the
frequency of p53 protein expression by immunohistochemistry in primary breast
carcinomas in a series of Asian women. The expression data were further correlated
with clinicopathological parameters such as histological grade of the tumours, stage of
disease at presentation and survival.
(3) Evaluation of p53 mutations in paired samples of DCIS and normal
breast tissues
While there are abundant data to support that p53 mutations are important in the
development of invasive breast cancer, there is a paucity of data on the role of p53
aberrations at the stage of preinvasive disease, i.e., DCIS. In this project, mutational
analysis of p53 was performed in a series of DCIS lesions and their corresponding
normal breast tissues. Tissue microdissection was employed to procure tissue samples
representing specific histologic subtypes as DCIS lesions are usually morphologically
heterogeneous. The aims of this segment were two-fold: 1) to determine the frequency




which p53 mutations contribute to breast carcinogenesis. The data were further
correlated with histologic subtypes and nuclear grade of the lesions.
(4) Mutational and expression analyses of E2F-1 and E2F-4 in primary and
metastatic breast cancers, and corresponding normal breast tissues
While genetic and expression analysis of the E2Fs have recently been reported in
human malignancies such as bladder and gastrointestinal tumours (Rabbani et al.,
1999; Suzuki et al., 1999), such data pertaining to breast carcinoma are limited. It has
been reported that recombinant adenovirus-mediated overexpression of E2F-1
resulted in apoptosis in breast cancer cell lines (Hunt et al, 1997). With the very
recent data on the functional relationship between E2F-1 and the p14ARF-hdm2-p53
pathway, as well as, the paucity of data on the role of E2Fs in breast carcinoma, this
project aimed to determine the role of the transcription factors, E2F-1 and E2F-4, in
breast carcinogenesis. Mutational and expression analyses of E2F-1 and E2F-4 were
performed not only in primary breast cancers, but, included their corresponding
metastatic lymph nodal tissues and normal breast tissues, as well as, a series of human
breast cancer cell lines.
Part of the work was performed in Singapore while some were performed at
Memorial Sloan-Kettering Cancer Centre in New York, USA, as the author received 2
overseas cancer research fellowships (from the National Medical Research Council,
Singapore and Singapore Cancer Society) for a 2-year period.
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CHAPTER 2
INVESTIGATION OF GENETIC ALTERATIONS OF THE 






The high frequency of alterations in the tumour suppressor gene p53 in human
malignancies, including breast cancer, suggests that the gene plays a central role in
the carcinogenesis of different tumours. The cellular functions of p53 include
induction of cell cycle arrest and apoptosis in response to DNA damage and
oncogenic signals in order to maintain genetic integrity. Inactivating mutations in p53
result in the loss of its negative growth regulatory function and increased cell
proliferation. Alterations in this gene have been identified in 14% to 46% of breast
carcinomas (Osborne et al., 1991; Runnebaum et al., 1991; Elledge et al., 1993;
Bergh et al., 1995; Kovach et al., 1996; Cuny et al., 2000), depending on the method
of detection used and the regions of the gene analysed. Alternatively, the p53 protein
may be inactivated by cellular oncoproteins, such as hdm2 (Momand et al., 1992;
Oliner et al., 1993), and viral proteins (Levine, 1990) when the gene is intact.
The activity of p53 and expression of hdm2 in a cell are regulated by an
autoregulatory feedback loop (Wu et al., 1993). The p53 protein positively regulates
hdm2 by activating hdm2 gene expression while hdm2 inhibits p53-mediated
transactivation by binding the p53 protein (Momand et al., 1992; Oliner et al., 1993;
Chen et al., 1996). hdm2 also targets the p53 protein for rapid proteasomal
degradation (Haupt et al., 1997; Kubbutat et al., 1997). When a cell encounters DNA
damage, this feedback loop is modulated such as p53 protein is stabilised to allow for




studies, hdm2 overexpression increased the tumorigenic potential of rodent fibroblasts
(Fakharzadeh et al., 1991) and overcame wildtype p53-mediated suppression of
transformed cell growth (Finlay, 1993). The hdm2 gene has been shown to be
abnormally upregulated in breast tumours by gene amplification and overexpression
(Marchetti et al., 1995; McCann et al., 1995; Courjal et al., 1996; Cuny et al., 2000),
suggesting a possible role for hdm2 alterations in breast tumorigenesis.
The recent discovery of p14ARF, an alternate transcript of the INK4A tumour
suppressor locus, and the elucidation of its direct interaction with hdm2 established a
functional link between p14ARF and p53 (Pomerantz et al., 1998; Stott et al., 1998;
Zhang et al., 1998). The p14ARF protein inhibits cell cycle progression by inducing G1
and G2/M phase arrest in a p53-dependent manner (Kamijo et al., 1997; Pomerantz et
al., 1998, Stott et al., 1998). p14ARF stabilises p53 by binding hdm2, thereby blocking
hdm2-induced degradation of p53 and enhancing p53-dependent transactivation and
growth inhibition (Pomerantz et al., 1998; Stott et al., 1998; Zhang et al., 1998).
Furthermore, it has been shown that the peptide encoded by exon 1β of INK4A alone
is both necessary and sufficient for inducing cell cycle arrest (Quelle et al., 1997).






Considering the functional relationship among these three components, the presence
of inactivating mutations in p14ARF or hdm2 amplification may be biologically
equivalent to mutational inactivation of p53. Although there are a few reports
comparing the protein expression of p53 and hdm2 in breast carcinomas with
inconsistent results (Marchetti et al., 1995; McCann 1995; Courjal et al., 1996), the
relationship between these 2 genes at the genetic level has not been described. The
role of genetic alterations in p14ARF and this p14ARF-hdm2 -p53 pathway is also
unknown in the development of breast cancer. In this study, we investigated the
components of this regulatory pathway for genetic alterations which might result in
the inactivation of p53, thereby allowing uninhibited cell proliferation, in 14 human
breast cell lines and 36 primary breast carcinomas. Specifically, we analysed exons 5
- 9 of p53 by PCR-SSCP, and exon 1β of p14ARF for mutations or deletions by PCR-
SSCP and Southern blot analysis. We also evaluated the expression of the p14ARF β





2.3 MATERIALS & METHODS
2.3.1 Human Tissue Samples
Human tissue samples utilized in this study were obtained from the Breast Service,
Department of Surgery at the Memorial Sloan-Kettering Cancer Center in New York
City, USA, by courtesy of Dr Kimberly J Van Zee. Fresh frozen samples from 36
primary invasive breast carcinomas were obtained from mastectomy specimens. The
samples were procured at the time of surgery and snap frozen in liquid nitrogen. The
study was approved by the Institution Review Board prior to tissue collection.




Table 3.  Tumour Characteristics of 36 Invasive Breast Carcinomas
Characteristics Number (%)
Histologic subtype
     Invasive ductal carcinoma 34 (94.4%)
     Invasive lobular carcinoma 2 (5.6%)
Estrogen receptor statusa
     Positive 16 (44.4%)
     Negative 11 (30.6%)
Progestrogen receptor statusa
     Positive 14 (38.9%)
     Negative 13 (36.1%)
Stage of diseaseb
     I 6 (16.7%)
     II 23 (63.9%)
     III 7 (19.4%)
a Hormonal receptor status of 9 cases were not known.
b According to AJCC Staging System (Appendix 1).
2.3.2 Human Breast Cell Lines
All cell lines were obtained from the American Type Culture Collection (Rockville,
MD). These included 13 breast cancer cell lines (BT-474, BT-549, Hs 578T, MCF7,
MDA-MB-134, MDA-MB-231, MDA-MB-435, MDA-MB-436, MDA-MB-453,
MDA-MD-468, SK-BR-3, T-47D and ZR-75-1), one normal mammary epithelial cell




grown in DMEM:Ham’s F12 supplemented with 10% fetal bovine serum (FBS) while
JAR was grown in RPMI 1640 supplemented with 10% FBS. The esrogen and
progesterone receptor status of the cell lines are shown in Table 4.
Table 4.  Estrogen and Progesterone Receptor Status of Human Breast Cell Lines
Cell line Estrogen Receptor Progesterone Receptor
BT-474a - +
BT-549b - NA











a Maemura et al., 1995
b Engel et al., 1978
c Hackett et al., 1997





Genomic DNA was extracted from the tissues and cell lines using the
phenol/chloroform method followed by ethanol precipitation (Sambrook et al., 1989).
Briefly, the tissue samples were pulverised, suspended in 2 ml TE (2M Tris-HCl [pH
7.4], 0.5M EDTA [pH 8.0]) and incubated with 0.1 ml 20% SDS (final 1%) and 20
mg/ml proteinase K overnight at room temperature with shaking. Cell lines that grew
in monolayers were washed with PBS and trypsinised. Cells were retrieved by repeat
centrifugation and resuspended in 1 volume of digestion buffer (100 mM NaCl,
10mM Tris HCl [pH 7.4], 25 mM EDTA, 0.5% SDS) and 10 mg/ml proteinase K. The
cells were incubated overnight at room temperature with shaking after which an an
equal volume of phenol/chloroform was added to all tissue samples and cell lines.
After an hour, the samples were centrifuged at 5000 rpm for 5 min, and the aqueous
phase was transferred to a clean tube to which 0.1 volume of 3M sodium acetate (pH
6.0) and 2 volumes of cold ethanol were added. This mixture was kept at –70oC for an
hour after which centrifugation was done for 10 min. The resultant pellets were rinsed




2.3.4 Mutational Analysis of p53
2.3.4.1 Polymerase Chain Reaction – Single-Strand Conformation Polymorphism
Analysis (PCR-SSCP)
For the 36 cases of invasive breast cancers, exons 5-9 were individually amplified by
polymerase chain reaction (PCR) as previously described (Gaidano et al., 1991) using
published primers (Anelli et al., 1995) (Table 5), except for the following three
primers: exon 5 forward, exon 6 forward and exon 8 forward. These were designed




Table 5.  Primers for PCR Amplification of p53
Exon Primer Sequence (5’Æ 3’) Annealing
Temperature
5 Forward AGAATTCCTCTTCCTGCAGTACTCCCCTG 63oC
Reversea AGCTGCTCACCATCGCTATCTGAGCA
6 Forward GATTGCTCTTAGGT-CTGGCCCCTC 66oC
Reversea GGCCACTGACAACCACCCTTAACC
7 Forwarda TGTTGTCTCCTAGGTTGGCTCTGA 63oC
Reversea CAAGTGGCTCCT-GACCTGGAG
8 Forward CCTATCCTGAGTAGTGGTAATCTA 63oC
Reversea GTCCTGCTTGCTTACCTCGCT
9 Forwarda TTGCCTCTTTCCTAGCACTCCCCA 63 oC
Reversea CAAGACTTAGTACTGAAGGGTGA
a Primer sequences from Anelli et al., 1995.
One hundred nanograms of genomic DNA was amplified using 10 pmol of each
primer, 2.5 µM dNTPS, 1 µCi of of [α-32P] dCTP (3000 Ci/mmol; Dupont NEN
Research Products, Boston MA), 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1 mM
MgCl2, 0.5U of Taq polymerase, in a final volume of 10 µL. Reaction conditions
consisted of an initial denaturation step at 94°C for 5 min, followed by 30 cycles of




a final extension step at 72°C for 5 min in a thermal cycler. The PCR products were
loaded onto a 6% polyacrylamide/TBE gel. Gels were ran at 40 watts for 4 hours at
4°C in 0.5 X TBE. Autoradiography was performed with intensifying screens.
2.3.4.2 Direct Sequencing
Invasive breast cancers and cell lines that demonstrated mobility shifts on SSCP
analysis were subjected to bi-directional sequencing to characterise the genetic
alterations. The aberrant bands were excised from the gel, eluted in water and
sequenced according to the Sequenase version 2.0 protocol (United States
Biochemical Corporation, Cleveland, OH). Sequences were visualised by
autoradiography.
2.3.5 Mutational Analysis of p14ARF
2.3.5.1 PCR-SSCP Analysis
Amplification of exon 1β was performed using published primers (Mao et al., 1995)
in 36 invasive breast cancers. Five hundred nanograms of template was subjected to
PCR with 0.2µl of [α-32P] dCTP, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 200 µM
dNTPs, 20 pmol of each primer, 1U Taq polymerase and 5% DMSO in a 50µl
reaction volume. Reaction conditions consisted of an initial denaturation step at 95°C
for 5 min, followed by 30 cycles of 95°C for 30 sec, 55°C for 30 sec and 72°C for 40




of the PCR product were digested with 5 units of MSP I at 37°C into 3 smaller
fragments of 121, 130 and 189 bp and diluted in denaturing loading buffer. Both
digested and non-digested products were resolved on a 6% polyacrylamide gel and the
bands were visualised by autoradiography.
2.3.5.2 Southern Blotting
As deletion of p14ARF exon 1β was detected among the human breast cell lines but not
in the primary breast cancers, it was pertinent to demonstrate that gene deletion was
not masked by contaminating normal tissue. In eight tumours with sufficient available
DNA (Cases 4T, 10T, 23T, 25T, 26T, 32T, 33T and 37T), Southern blotting was
performed using the 440-bp gel purified PCR product of p14ARF exon 1β as a probe.
Ten micrograms of genomic DNA were digested with EcoRI restriction endonuclease.
The digests were resolved on 1% agarose gel, transferred to Hybond N+ membranes
(Amersham, Arlington Heights, IL) and hybridised with Hybrisol (Oncor, Inc.,
Gaithersburg, MD) at 50oC overnight with probes labelled to high specific activity
using [α-32P] dCTP (6000Ci/mmol)(Dupont NEN Research Products). The
membranes were washed at a high stringency with 0.1X SSC/0.1% SDS at 50oC for





2.3.6 Gene Amplification of hdm2
2.3.6.1 Differential PCR
This was performed for as described by Frye et al. (1989). The hdm2 gene was co-
amplified with a reference gene, phenylalanine hydroxylase (PAH), with
incorporation of [α-32P] dCTP (6000Ci/mmol; Dupont NEN Research Products) using
published primer sequences and amplification protocol (Reid et al., 1996). The
primers for HDM2 were: forward, 5’-GGTTGGATCAGGATTCAGTT-3’; reverse,
5’GAGTTCTTGTCCTTCTTCAC-3’, and those for PAH were: forward, 5’-
ATGCCATGAGAACTGTCTT-3’; reverse, 5’-TTTGGGTGTATGGGTCGTAG-3’.
The amplification consisted of 1 cycle at 94oC for 9 min, followed by 30 cycles of
94oC for 1 min, 50oC for 1 min and 72oC for 1 min, and a final extension at 72oC for 7
min. The PCR products were electrophoresed in a 10% polyacrylamide/TBE gel
(Biorad, Hercules, CA) and visualised by autoradiography. The choriocarcinoma cell
line JAR representing 4-fold amplification of hdm2 (Seki et al., 1997) served as a
positive control. Placental DNA (Oncor Inc., Gaithersburg, MD), DNA from the
adjacent normal breast tissue of one tumour sample and a water blank were used as
negative controls. All controls were included in each set of PCR reactions and gel run,
and the analysis was repeated for all samples.
Band intensities were quantitated by the ChemiImager™ 4000 (Alpha Innotech Corp.,
San Leandro, CA). The relative ratio of hdm2/PAH PCR products was computed for




ratios were converted to a semi-quantitative scoring of amplification by comparison
with the results of the normal control. The densitometric ratios were further
corroborated by a visual qualitative interpretation of the autoradiograms.
 
2.3.7 mRNA Expression of p14ARF
2.3.7.1 RNA Extraction
Total RNA was isolated by the TRIzol reagent (Life Technologies, Inc., Gaithersburg,
MD) from 36 invasive breast carcinomas and 14 human breast cell lines according to
the manufacturer’s protocol. 
2.3.7.2 Northern Blotting
Four µg of total RNA was reverse transcribed using random hexamers and
Superscript II reverse transcriptase (Gibco-BRL, Gaithersburg, MD). The transcripts
were PCR amplified using a published protocol and primers (Stone et al., 1995) and
visualised by ethidium bromide staining after agarose gel electrophoresis. To confirm
the integrity of the RNA, the cDNAs were amplified with β-actin specific primers that
do not co-amplify processed pseudogenes (Raff et al., 1997). All reactions were
repeated and controlled with the omission of reverse transcriptase. All cell lines and
only 9 tumours could be analysed for expression of the p14ARF transcript. Sufficient




2.3.8 Safety Precautions in Use of Radioactive Materials
Handling and disposal of radioactive materials were in strict accordance with the
laboratory’s regulations. Gloves, overalls and goggles were worn at all times. A badge
to monitor personal exposure to radioactivity was also worn at all times. The badges
were checked by the Nuclear Medicine Department once a month. Radioactive
materials and products of experiments were discarded in appropriate bins designated
for radioactive materials. After handling of such materials, hands and overalls were
checked with a Geiger counter to ensure no accidental contact of skin or garment with
radioactive materials. The work surfaces were similarly checked for contamination




2.4 RESULTS IN PRIMARY INVASIVE BREAST CARCINOMA
2.4.1 Mutational Analysis of p53
Band shifts were detected in 8 of the 36 (22%) breast carcinomas, all of which were
invasive ductal cancers, by PCR-SSCP analysis (Figure 12).
Fig 12.  SSCP analysis of p53 exon 8 in primary breast carcinomas. The tumour
sample 53T demonstrated mobility shift (marked with an asterisk).
Missense mutations were confirmed and characterized by bi-directional sequencing in
7 tumours. The eighth tumour (Case 4T) contained a substitution of a single
nucleotide (AÆG) at codon 213 in exon 6 which does not result in a change in the




Fig 13.  Sequence analysis of p53 exon 8 in Case 53T. Missense mutation (CGT Æ
CAT, Arg Æ His) at codon 273 resulting from a substitution of a single nucleotide
was identified. The mutated nucleotide (GÆA) is indicated by an arrow.
Fig 14.  Sequence analysis of p53 exon 6 in Case 4T. A polymorphism comprising a
single nucleotide substitution (CGA Æ CGG, Arg Æ Arg) at codon 213 was




The genetic alterations in p53 among the 36 primary breast carcinomas are
summarised in Table 6.
Table 6.  p53 Alterations in 36 Primary Invasive Breast Carcinomasa
Tumoursb Exon Codon Nucleotide substitution Amino acid change
    4T 6 213 CGA→ CGG Arg → Arg
  19T 5 175 CGC → CAC Arg → His
  20T 7 238 TGT → CGT Cys → Arg
  30T 7 248 CGG → CAG Arg → Gln
  33T 8 273 CGT → CAT Arg → His
  34T 7 248 CGG → TGG Arg → Trp
  52T 7 234 TAC → AAC Tyr → Asn
  53T 8 273 CGT → CAT Arg → His
aAll are missense mutations except for tumour sample 4T which contained a
polymorphism.




2.4.2 Gene Amplification of hdm2
Differential PCR has been shown to be capable of detecting two-fold amplification of
the target gene (Frye et al., 1989; Reid et al., 1996; Seki et al., 1997). Hence, the gene
was considered amplified when the normalized hdm2/PAH ratio of a sample was
higher than the mid-point between that for placental DNA and JAR (four-fold
amplification) which is equivalent to two-fold amplification of the gene. Four primary
ductal carcinomas had densitometric ratios higher than that of placental DNA and the
normal tissue sample. Two-fold amplification of hdm2 was detected in two tumours
(Figure 15). Both tumours contained wild-type p53 and p14ARF genes. The other two
tumours with values greater than that of placental DNA but less than the mid-point
between placental DNA and JAR were not considered to be amplified to avoid false
positives.
Fig 14.  Detection of hdm2 gene amplification by differential PCR in primary breast
carcinomas using phenylalanine hydroxylase (PAH) as the reference gene. The cell
line JAR representing 4-fold hdm2 gene dosage served as a positive control while
placental DNA and normal breast tissue (30N) served as negative controls. Two-fold
increase in hdm2 gene amplification was detected in Cases 17T and 36T (marked with





2.4.3 Mutational Analysis of p14ARF
No band shifts were present in any of the 36 primary breast carcinomas upon SSCP
analysis of p14ARF exon 1β. A representative gel is shown in Figure 16.
Fig 16.  SSCP analysis of p14ARF exon 1β in primary invasive breast carcinomas. No
band shift was detected. Negative, water blank to ensure the absence of
contamination.
To demonstrate that gene deletion was not masked by contaminating normal tissue,
Southern blotting was performed in 8 tumours with sufficient available DNA, using
the gel purified p14ARF PCR product as a probe. This confirmed the absence of gene




2.4.4 Analysis of mRNA Expression of p14ARF
The p14ARF β transcript was detectable in all 9 breast tissue samples examined by RT-
PCR (Figure 17).
Fig 17. Analysis of p14ARF expression by RT-PCR in primary invasive breast
carcinomas. The total RNA was reverse transcribed with (+) and without (−) reverse
transcriptase for each sample. Amplification of β-actin was used to demonstrate RNA




2.5 RESULTS IN HUMAN BREAST CELL LINES
2.5.1 Mutational Analysis of p53
Among the 14 human breast cell lines, 7 (50%) demonstrated mobility shifts upon
SSCP analysis. Similar to the human tissue samples, missense mutations were
characterized by bi-directional sequencing in all 7 cell lines. These mutations have
been described by Bartek et al. (1990). The cell line MDA-MB-453 which has been
reported to contain a deletion of 30 base pairs in the 3’ end of exon 11 (Runnebaum et
al., 1991) did not demonstrate a mobility shift on SSCP as our analysis was confined
to exons 5 - 9. The genetic alterations are summarised in Table 7.
Table 7.  Missense Mutations in p53 Identified in 7 of 14 Human Breast Cell Lines
Cell lines Exon Codon Nucleotide substitution Amino acid change
BT-474 8 285 GAG → AAG Glu → Lys
BT-549 7 249 AGG → AGC Arg → Ser
Hs 578T 5 157 GTC → TTC Val → Phe
MDA-MB-231 8 280 AGA → AAA Arg → Lys
MDA-MB-468 8 273 CGT → CAT Arg → His
SK-BR-3 5 175 CGC → CAC Arg → His




2.5.2 Gene Amplification of hdm2
None of the cell lines showed hdm2 gene amplification (Figure 18). Southern blotting
was performed in all 14 cell lines to confirm the results obtained by differential PCR,
using a human cDNA fragment probe (data not shown).
Fig 18.  Detection of hdm2 gene amplification by differential PCR in human breast
cell lines, using phenylalanine hydroxylase (PAH) as the reference gene. The cell line
JAR representing 4-fold hdm2 gene dosage served as a positive control while
placental DNA and normal breast tissue (30N) served as negative controls. Negative,
a water blank was included in every gel to ensure the absence of contamination. None




2.5.3 Mutational Analysis of p14ARF
There was no conformational shift observed on SSCP analysis. However, exon 1β
was homozygously deleted in two of the 14 (14%) cell lines, MDA-MB-231 (Figure
19) and MCF-10A (not shown). 
Fig 19. SSCP analysis of p14ARF exon 1β in human breast cell lines. MDA-MB-231




2.5.4 Analysis of mRNA Expression of p14ARF
The p14ARF β transcript was not detectable in four of the 14 (28%) breast cell lines;
two of which contained deletion of p14ARF exon 1β (MDA-MB-231 and MCF-10A)
(Figure 20).
Fig 20.  Analysis of p14ARF expression by RT-PCR in breast cell lines. The total RNA
was reverse transcribed with (+) and without (−) reverse transcriptase for each
sample. Amplification of β-actin was used to demonstrate RNA integrity. The β
transcript was not detectable in MDA-MB-231.
The other two cell lines had an intact exon 1β (Hs 578T and MCF7). The remaining




The genetic alterations in the p14ARF-hdm2-p53 pathway in the 14 human breast cell
lines are summarised in Table 8.
Table 8.  Genetic Alterations in the p14ARF-hmd2-p53 Pathway in the 14 Human
Breast Cell Lines






BT-474 mut wt + −
BT-549 mut wt + −
Hs 578T mut wt − −
MCF7 wt wt − − 
MCF-10A wt del − −
MDA-MB-134 wt wt + −
MDA-MB-231 mut del − −
MDA-MB-435 wt wt + −
MDA-MB-436 wt wt + −
MDA-MB-453  mutd wt + −
MDA-MB-468 mut wt + −
SK-BR-3 mut wt + −
T-47D mut wt + −
ZR-75-1 wt wt + −
aAbbreviations: mut, mutant; wt, wild-type; del, deleted.
b(+) indicates presence and (-) indicates absence of detectable transcript.
c(-) indicates absence of gene amplification.





2.6.1 p53 Mutations in Breast Cancer
The tumour suppressor p53 plays a critical role in many cellular functions, including
regulation of normal cell growth and division, DNA repair and apoptosis (Haffner and
Oren, 1995). It maintains genetic integrity by inducing cell cycle arrest and apoptosis
in response to DNA damage and oncogenic signals (Reviewed in Asschert, 1998). It
acts as a transcription factor and binds to genomic DNA in a sequence-specific
manner via its DNA binding domain (Levine, 1997). Mutated p53 proteins cannot
bind to DNA-specific sequences (Milner and Medcalf, 1991) and hence, are unable to
transactivate genes responsive to wild-type p53 protein (Farmer et al., 1992; Kern et
al., 1992). In addition, the mutated protein can bind to the wild-type protein,
abrogating the functions of the wild-type protein (Milner and Medcalf, 1991).
There are data to support the relevance of p53 mutations in the tumorigenesis and
progression of breast carcinoma. Not only is p53 the most common genetic target in
breast cancer, a recent report suggests that mutations of p53 may be important in the
development of mammary ductal carcinoma in situ (Done et al., 1998), the precursor
of invasive ductal carcinoma. Exons 5 – 9 of p53 were analysed for several reasons.
The p53 gene contains 11 exons and exon 1 is non-coding (Soussi et al., 1990). It has
five evolutionarily highly conserved domains, 4 of which are encoded by exons 5 – 8




spectrum in various solid tumours and haematological malignancies, and reported that
98% of missense mutations occurred within exons 5 – 8. Hartmann et al. (1995)
examined all 11 exons of p53 in 194 primary breast cancers. 33% (64/194) of breast
cancers contained mutations in exons 5 – 8 and only 9% (18/194) had mutations
outside exons 5 – 8. No alterations were identified in exons 1, 2, 3 and 11.
In the present study, p53 mutations were identified in 19% of the primary breast
cancers and 50% of the human breast cell lines. All were missense mutations and
occurred within exons 5 - 8, in agreement with Soussi et al. (1990) who reported that
such mutations predominate and cluster in this highly conserved region of the gene.
The frequency of mutations within exons 5 - 9 of the gene detected by SSCP analysis
in previous studies ranges from 14 to 42% in breast cancers (Osborne et al., 1991;
Runnebaum et al.,1991; Elledge et al., 1993). The higher incidence of point mutations
in breast cancer cell lines compared to primary tumours has also been observed by
other investigators (Runnebaum et al., 1991). The polymorphism identified in one
tumour at codon 213 (CGA Æ CGG; Arg Æ Arg) has been reported in breast and
lung cancers (Carbone et al., 1991). This polymorphism may be mistaken as a
mutation if analysis of the gene is performed by SSCP alone as it demonstrates an




2.6.2 hdm2 Gene Amplification in Breast Cancer
It is believed that the reciprocal regulation between the hdm2 and p53 proteins is
necessary to maintain controlled cell growth (Wu et al., 1993). hdm2 gene
amplification and overexpression results in transcriptional silencing of p53, allowing
escape from p53-regulated growth control. In addition, hdm2 also has tumorigenic
potential (Fakharzadeh et al., 1991; Finlay, 1993).  Amplification of hdm2 was
observed in two (7%) primary breast cancers in our study. This low prevalence among
tumours is consistent with the overall low frequency (6%) of hdm2 gene amplification
in breast carcinomas reported to date (reviewed by Momand et al., 1998). None of the
breast cell lines demonstrated hdm2 gene amplification in our study. One would
expect a higher frequency of this abnormality in cell lines as immortalized cells in
culture have the propensity to accumulate genetic alterations. The results obtained by
differential PCR were confirmed by Southern blotting in all the cell lines. 
hdm2 gene amplification has been observed in a third of human soft tissue sarcomas
(Oliner et al., 1992; Leach et al., 1993; Cordón-Cardó et al., 1994), implicating such
amplification in the development of these tumours. However, its role appears to be
less significant in epithelial tumours. In lung and urothelial cancers, the low frequency
of hdm2 amplification as compared to the high percentage of p53 genetic alterations
suggests that the p53 pathway may be preferentially inactivated by mutations in p53
in such cancers (Momand et al., 1998). This could be the scenario in breast




mRNA in breast cell lines in the absence of gene amplification. Bueso-Ramos et al.
(1996) reported overexpression of hdm2 mRNA and protein in 73% of human breast
carcinomas in the absence of gene amplification. These data suggest possible
regulation of the gene at the transcriptional or post-transcriptional level. Nonetheless,
our results indicate that although hdm2 amplification is an uncommon event in breast
cancer, it does occur and may play an important role in a small proportion of breast
carcinomas.
2.6.3 p14ARF Gene Mutation and mRNA Expression in Breast Cancer
p14ARF is a putative tumour suppressor gene. p19ARF-null mice showed increased
tumour development and embryonic fibroblasts of p19ARF-null mice were
immortalised in culture (Kamijo et al., 1997). The p14ARF protein induces cell cycle
arrest by stabilising p53. p14ARF binds to hdm2, which prevents the interaction
between hdm2 and p53 (Tao and Levine, 1999b; Weber et al., 1999), and thereby,
prevents hdm2-induced degradation of p53 (Pomerantz et al., 1998; Stott et al., 1998;
Zhang et al., 1998). Hence, inactivation of p14ARF could be an alternative mechanism
of p53 inactivation.
In this study of 36 primary breast cancers, no mutation in p14ARF was identified. The
absence of mutations in exon 1β of p14ARF in breast carcinomas is not surprising.




melanoma (Fitzgerald et al., 1996) and tumour-derived lung, bladder and glioma cell
lines (Stone et al., 1995). However, two breast cell lines (MCF-10A and MDA-MB-
231) were found to have an exon 1β deletion with corresponding absence of
detectable mRNA. The β transcript was not detectable in two additional cell lines, Hs
578T and MCF7, despite the presence of an intact exon 1β. Van Zee and co-workers
(1998) at Memorial Sloan-Kettering Cancer Centre have previously reported the
homozygous deletion of exon 1α and the common exons 2 and 3 of the INK4A locus
in MCF7. Analysis of the INK4A gene in Hs 578T demonstrated similar homozygous
deletion of this gene (data not shown). The reverse primer used in the RT-PCR
analysis of the p14ARF β transcript is within exon 2 which is likely to be responsible
for the apparently negative expression of p14ARF in these two cell lines.
 
Although mutations of p14ARF do not appear to be an important mechanism in the
tumorigenesis of breast cancer, this gene may be inactivated by alternative
mechanisms. Post-translational regulation of p14ARF activity has been suggested in
lung cancers and haemopoietic cell lines because the protein was not detected in
samples that expressed the mRNA (Valle et al., 1997; Gazzeri et al., 1998). While
p19ARF-deficient mice showed no increased susceptibility to breast tumours (Kamijo
et al., 1997), there is no data on the expression of p14ARF in normal and malignant
human breast tissues to discount its possible role in breast carcinogenesis. Further
work should be done to evaluate the expression of p14ARF in normal breast
epithelium, as well as, to determine if the expression of the mRNA and protein are




2.6.4 Is There A Reciprocal Relationship Between p53 Mutations and hdm2
Gene Amplification, and Between p53 and p14ARF Mutational Events?
A recently published hdm2 gene amplification database suggests that mutations in p53
and hdm2 gene amplification do not generally occur within the same tumour since
p53 and hdm2 are directly antagonistic (Momand et al., 1998). Likewise, the rare
occurrence of co-mutation of p53 and p14ARF supports the hypothesised reciprocal
relationship between p53 and p14ARF mutational events (Pomerantz et al., 1998).
Hence, one would predict that aberrations in either p14ARF or hdm2 are more likely to
occur in the presence of a wild-type p53 and vice versa. These reciprocal relationships
were observed in the present study. The 7 primary tumours with mutant p53 did not
have p14ARF alterations or hdm2 gene amplification. The two tumours that
demonstrated hdm2 gene amplification did not contain genetic alteration in either p53
or p14ARF. This was also the case in the 7 cell lines with p53 mutations and one cell
line had a deletion of p14ARF exon 1β alone. There was an exception; the cell line





IMMUNOHISTOCHEMICAL ANALYSIS OF p53 IN
PRIMARY BREAST CARCINOMA AND CORRELATION WITH
CLINICOPATHOLOGICAL PARAMETERS




Evaluation of the tumour suppressor p53 in human malignancies has been performed
in mainly 2 ways: 1) identification of mutations at the genetic level, and 2)
identification of the mutant p53 protein by immunohistochemical analysis. The wild-
type p53 protein has a very short half-life of less than 30 min (Oren et al., 1981;
Reich et al., 1983; Rogel et al., 1985). Hence, the level of the protein is very low in
normal cells and virtually undetectable by immunohistochemistry due to its rapid
degradation. However, mutant p53 proteins have extended half-lives and are found in
tumour cells in higher concentrations (Oren et al., 1981; Reich et al., 1983). Thus, the
recognition of p53 protein in the cell nucleus by immunohistochemistry is thought to
be due to the presence of the mutated form (Lane and Benchimol, 1990; Montenarch,
1992) which is incapable of its normal physiological functions.
While there are studies that show good correlation between p53 mutational status and
nuclear accumulation of p53 protein (Davidoff et al., 1991b; Thor et al., 1992;
Umekita et al., 1994b), there are an equal number of reports that p53
immunoexpression might not be a highly sensitive marker of p53 gene mutations
(Dunn et al., 1993; Lohmann et al., 1993; Hurlimann et al., 1994). The incidence of
p53 positivity by immunohistochemical studies tends to be higher than that of gene
mutations detected by DNA-based methods. The most commonly employed DNA-
based technique is SSCP analysis which detects only missense mutations. Although
the sensitivity of this method for detection of p53 mutations has been estimated at
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more than 90% (Moyret et al., 1994), other types of genetic alterations such as
frameshift and large genomic deletions may be present. In addition, mutations could
occur outside the gene regions analysed as most studies examined only the highly
conserved regions of the gene. Alternatively, immunohistochemical studies may
overestimate the incidence of mutations. Stabilisation of the p53 protein could also be
due to non-mutational means like binding of the protein to viral oncoproteins such as
hdm2. Nonetheless, immunohistochemical staining of nuclear p53 protein has been
widely used as a surrogate marker of underlying p53 mutations as it is relatively
inexpensive and easy to perform, especially on a large number of tumours which
makes it feasible for routine p53 analysis in a clinical setting.
p53 has been extensively investigated to establish its prognostic value in breast
cancer. While axillary lymph nodal status is the single most important prognostic
factor in breast cancer (Fisher et al., 1983), it cannot entirely explain the different
prognoses observed in certain subgroups of patients, either with node positive or node
negative disease (Callahan, 1992; Joensuu and Toikkanen, 1992). Of particular
interest is the group of women with node negative early stage breast cancer and yet an
unfavourable prognosis. Due to the high frequency of p53 alterations in breast cancer,
much attention has been focused on this molecular marker to determine if it could
help identify women who are at higher risk of relapse and death. Many studies have
examined the association between p53 immunohistochemical expression and
prognosis of breast cancer. The majority of these studies have reported p53 expression
to be inversely correlated with survival (Thor et al., 1992; Allred et al., 1993; Barnes
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et al., 1993; Friedrichs et al., 1993; Slivestrini et al., 1993; Beck et al., 1995;
MacGrogan et al., 1995; André et al., 1997) while a few studies showed no influence
on survival (Bosari et al., 1992; Hurlimann et al., 1993; Haerslev et al., 1995; Rosen
et al., 1995). However, differences in technique and variability in the frequency and
intensity of immunoreactivity with different antibodies have made it difficult to
compare results. More significantly, there is very limited data on p53 expression and
its prognostic value in Asian populations. To date, there are only data from the
Japanese population. Umekita et al. (1994a) reported p53 positive immunoreactivity
in 29% of 83 cases of invasive ductal carcinomas examined, with an association with
high histological grade. However, no survival analysis was performed.
3.2 OBJECTIVES
In view of the paucity of data pertaining to Asian populations, in this study, p53
protein expression was evaluated by immunohistochemistry in a series of Asian
women. The aims were to determine, among women in Singapore: 1) the frequency of
p53 immunopositivity in primary invasive breast cancers, 2) the correlation between
p53 nuclear staining status and pathologic parameters of histologic subtypes,
histologic grade and stage of disease, and 3) the association between p53
immunostaining and survival outcome. 
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3.3 MATERIALS & METHODS
3.3.1 Tissue Samples
Paraffin-embedded primary breast carcinomas from 105 women were used. These
patients were treated at the Singapore General Hospital between 1992 and 1993 and
underwent either modified radical mastectomy or wide excision of the tumour, with
axillary clearance. This study was approved by the Institution Review Board prior to
tissue collection. Eighty-seven (82.9%) of the women were Chinese, 14 (13.3%) were
Malays and 4 (3.8%) were Indians. The mean age was 52 years, with a range of 34 to
86 years. The mean size of the primary tumour was 4.7 cm, ranging from 0.5 to 11
cm. The histologic subtypes and histologic grades were reviewed and categorised
acoording to the system established by the National Co-ordinating Group for Breast
Screening Pathology (1995). Pathologic characteristics of these cancers are shown in
Table 9.
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Table 9.  Tumour Characteristics of 105 Invasive Breast Carcinomas
Characteristics Number (%)
Histologic subtype
     Ductal 96 (91.5)
     Lobular 5 (4.8)
     Medullary 1 (1.0)
     Mucinous 2 (1.9)
     Papillary 1 (1.0)
Histological gradea
     Well differentiated 22 (21.0)
     Moderately differentiated 50 (47.6)
     Poorly differentiated 29 (27.6)
Stage of diseaseb
     I 22 (21.0)
     II 55 (52.4)
     III 17 (16.2)
     IV 11 (10.5)
a Histologic grade was not assessable in 4 cases due to inadequate tumour tissue.
b Stage at presentation, according to AJCC Staging System (Appendix 1).
3.3.2 Immunohistochemical Analysis of p53
From the paraffin blocks, 4 µm sections were prepared on 5-
aminopropyltriethoxysilane (APES, Sigma) coated slides. The sections were
deparaffinised in xylene, hydrated in ethanol and rinsed with distilled water before
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incubation in 0.5 % hydrogen peroxide for 10 min to inactivate the endogenous
peroxidase activity. Antigen retrieval was achieved by heating the sections in a
microwave oven for 5 min at 98-100oC, placed in 10 mM citrate buffer (pH 6.0).
After washing in distilled water and 0.05M TBS (pH 7.6), blocking serum (Dako,
K681) was applied for 10 min to suppress non-specific binding of immunoglobulin.
The sections were then incubated with anti-p53 antibody Ab2 (mouse monoclonal
antibody from clone PAb 1801, Oncogene Science) at 1:200 dilution at room
temperature for 60 min. The sections were washed twice with TBS for 5 min each,
incubated with linking antibody (Dako) for 30 min, washed with TBS and incubated
with streptavidin peroxidase for 30 min. Diaminobenzidine (Dako, DAB 0.05M Tris-
HCl, pH 7.6, 10 mg/ml) was applied to the sections for 10 min at room temperature.
The sections were subsequently counterstained with haemotoxylin solution for 30 sec,
rinsed in water, dehydrated in increasing grades of ethanol, xylene and mounted in
depex. A breast tumour known to be reactive with p53 antibody was used as a positive
control in each staining batch. For negative control, the p53 antibody was omitted.
3.3.3 Statistical Analysis
The SPSS software package was used for statistical analyses. p53 immunostaining
was correlated with clincopathologic parameters such as histologic grade and stage of
disease using Chi-squared and Fisher exact test. Kaplan Meier analysis was performed
to determine the relationship between p53 nuclear staining status and survival of
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patients. p values of less than 0.05 were considered to be statistically significant
throughout the study.
3.4 RESULTS
3.4.1 Interpretation of p53 Immunostaining
For the interpretation of p53 positivity, only nuclear reactivity was considered as the
significance of cytoplasmic staining is unclear (Eeles et al., 1993). The degree of p53
staining was recorded in two ways: 1) the intensity of the nuclear reactivity which was
graded as weak, moderate or strong, and 2) the percentage of tumour cells with
positive nuclear staining. Fifty-six (53.3%) of the 105 breast carcinomas demonstrated
nuclear reactivity; 31 (29.5%) showed weak staining, 21 (20.0%) showed moderate
staining and 4 (3.8%) were strongly positive for p53. Examples of the various staining
intensities are shown in Figure 21.




(A)     (B)
  (C)      (D)
Fig 21.  Intensity of nuclear immunostaining of p53 in invasive ductal carcinoma. (A)
Negative staining. (B) Weak immunoreactivity. (C) Moderately positive p53 staining.
(D) Strong immunopositivity. (Magnification x 400)
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Among the 56 tumours that demonstrated immunoreactivity, nuclear staining was
present in fewer than 5% of the tumour cells in 19 (18.1%) cases, in 5-25% of the
tumour cells in 8 (7.6%) cases and in 25-50% in 16 (15.2%) cases. Thirteen (12.4%)
cancers demonstrated staining in more than 50% of the cells. A tumour was
considered as p53 positive when at least 5% of the cells showed nuclear reactivity to
the monoclonal antibody. A total of 37 (35.2%) of the 105 cancers were thus
classified as positive for p53 and 68 (64.8%) cases as p53 negative. In the evaluation
of the relationship between p53 nuclear staining status and clinicopathologic
characteristics, p53 positive tumours were compared to p53 negative tumours. 
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3.4.2 Correlation with Histological Subtypes and Grade
The p53 nuclear reactivity status among the various histological subtypes is shown in
the following Table.
Table 10.  Distribution of p53 Immunoreactivity Among Different Histological
Subtypes of Invasive Breast Cancer





Invasive ductal carcinoma (n = 96) 64 (61.0) 32 (30.5)
Invasive lobular carcinoma (n = 5) 2 (1.9) 3 (2.9)
Medullary carcinoma (n = 1) 1 (1.0) -
Mucinous carcinoma (n = 2) - 2 (1.9)
Papillary carcinoma (n = 1) 1 (1.0) -
Due to the overwhelming majority of invasive ductal carcinomas and the small
number of the other subtypes (invasive lobular, medullary, mucinous and papillary
carcinomas; n=9), statistical correlation between p53 positivity and histological
subtypes could not be performed.
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Among the 105 cases, 22 (21.0%) of the tumours were well differentiated, 50 (47.6%)
were moderately differentiated and 29 (27.6%) were poorly differentiated. The
histologic grade was not available for 4 cases. There was a significant correlation
between p53 positivity and histological grade of the tumours (Table 11). 
Table 11.  Correlation Between p53 Positivity and Histological Grade of 105 Invasive
Breast Cancers





Well differentiated (n=22) 18 (17.8%) 4 (4.0%)
Moderately differentiated (n=50) 36 (35.6%) 14 (13.9%)
Poorly differentiated (n=29) 12 (11.9%) 17 (16.8%)
p value* 0.004
* Chi-squared test
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3.4.3 Correlation with Stage of Disease
Staging of the tumours was according to the AJCC TNM Stage classification
(Appendix 1). Twenty-two (21.0%) of the patients had Stage I cancer, 55 (52.4%) had
Stage II , 17 (16.2%) had Stage III and 11 (10.5%) had Stage IV (metastatic) disease.
When the p53 nuclear staining status of cases with Stage IV disease was compared to
those without evidence of metastatic disease at the initial presentation, no correlation
was observed (Table 12).
Table 12.  Correlation Between p53 Immunoreactivity and Stage of Breast Cancer
Stage of Disease p53 nuclear staining (%)
Negative Positive
Stage I, II, III (n = 94) 62 (59.0%) 32 (30.5%)
Stage IV (n = 11) 6 (5.7%) 5 (4.8%)
p value* 0.51
* Fisher exact test
3.4.4 Correlation with Survival
Follow-up information was obtained from the Singapore General Hospital Breast
Cancer Registry. The duration of follow-up ranged from 0.05 to 6.6 years. Thirty-four
patients had deceased, one was lost to follow-up and the rest were live at the time of
analysis. Tumour recurrence was defined as local and/or regional relapse or detection
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of systemic metastases following treatment. The mean survival period was 5.0 years
and the mean time to first locoregional or systemic relapse was 5.2 years.
Kaplan Meier analysis was performed to determine the relationship between p53
nuclear staining status and survival in the 105 patients. Patients whose tumours
demonstrated positive p53 reactivity, i.e., tumours containing mutant p53, appeared to
have poorer survival compared to those with negative p53 staining. At 5 years, 52.7%
of patients with p53 positive tumours were alive compared to 72.3% of patients with
p53 negative tumours. The difference in overall survival was statistically significant
(p=0.046) (Figure 22).
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Similarly, the proportion of patients who were alive without disease at 5 years was
61.0% for those with p53 positive and 73.4% for those with p53 negative tumours
However, this difference did not reach statistical significance (p=0.067). (Figure 23).
Fig 23.  Disease-free survival analysis of patients with invasive breast carcinoma































3.5.1 Frequency of p53 immunopositivity
Using the definition of p53 immunopositivity as a tumour demonstrating p53 nuclear
reactivity in at least 5% of the cells, 35% of the breast cancers in this study were p53
positive. The incidence of p53 positive breast carcinomas in published
immunohistochemical studies ranges from 14% to 58% (Hanzal et al., 1992; Isola et
al., 1992; Thor et al., 1992; Friedrichs et al., 1993; Hurlimann, 1993; Lipponen and
Ji, 1993; Bhargava et al., 1994; Umekita et al., 1994a; Beck et al., 1995; Haerslev et
al., 1995; MacGrogan et al., 1995; Pietilainen et al., 1995; Rosen et al., 1995; André
et al., 1997). There are several technical reasons for the wide variability in the
reported frequencies. Prolonged storage of paraffin slides could result in alteration or
loss of some antigens (Jacobs et al., 1996; Bertheau et al., 1998) and different fixation
methods could lead to variable staining (Panault-Llorca et al., 1994; Jacobs et al.,
1996). In addition, different antibodies have varying sensitivity and specificity (Baas
et al., 1994; Busmanis et al., 1994; Press et al., 1994) and there is no consensus on the
scoring of immunostaining and presentation of results (Fisher et al., 1994; Van Diest
et al., 1997). Table 13 is a summary of published data.
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Hanzal et al., 1992 117 BP53-12 >5% 24.8
Isola et al., 1992 289 CM1 >20% 14.2
Thor et al., 1992 295 PAb 1801 Any positive cells 23
Hurlimann, 1993 235 CM1 Any positive cells 36
Lipponen and Ji, 1993 193 CM1 1 focus of positive
cells
58
Silvestrini et al., 1993 256 PAb 1801 >5% 44
Bhargava et al., 1994 198 PAb 1801 >1% 29.8
Umekita et al., 1994 93 CM1 >10% 31.1
Beck et al., 1995 462 DO-1 >10% 21.4
Haerslev et al., 1995 490 DO-7 Any positive cells 32.2
MacGrogan et al., 1995 942 DO-7 Any positive cells 32
Pietilainen et al., 1995 392 CM1 20-50% 14.6
Rosen et al., 1995 440 M 1801 >10% 21.5
André et al., 1997 353 CM1 >10% 17.2
The factor that accounts for the most part of the variability is most likely the criteria
for p53 immunopositivity. Authors who were more stringent in their definition
reported lower frequencies of p53 positivity.
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3.5.2 Is a p53 Positive Tumour More Aggressive Biologically?
Data suggest that p53 expression may be a biological marker of aggressive tumour
behaviour and unfavourable prognosis. Accumulation of p53 nuclear protein has been
associated with a number of adverse clinicopathologic factors in breast cancer. Thor
et al. (1992) and MacGrogan et al. (1995) reported significant association between
p53 protein accumulation and oestrogen and progesterone receptor negativity. Other
investigators have found significant positive correlation with high histologic grade
(Iwaya et al., 1991; Ostrowski et al., 1991; Thor et al., 1992; Barnes et al., 1993;
MacGrogan et al., 1995; André et al., 1997), high proliferation rate (Isola et al., 1992;
Allred et al., 1993), and aneuploidy (Allred et al., 1993). In this study 105 invasive
breast carcinomas, p53 protein expression was found to be significantly correlated
with high histological grade, as well. No relationship was found with stage of disease,
as has been reported by others (Thor et al., 1992; Ukemita et al., 1994; Beck et al.,
1995; André et al., 1997).
3.5.3 Is p53 Immunostaining Status of Prognostic Significance in Asian Breast
Cancer Patients?
Many immunohistochemical studies have examined the clinical significance of p53
protein expression as a prognostic indicator in breast cancer. Despite conflicting
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results, most studies with a reasonable sample size and at least 5 years of follow-up
suggest that p53 expression correlates with poorer survival (Table 14). 
Table 14.  Immunohistochemical Studies on p53 Protein Expression and Survival












Studies that showed association between p53 immunostaining and survival:
Thor et al., 1992 295 Any positive
cells
7 Yes Yes
Allred et al., 1993 700 Score >1 
(% + intensity)
5 Yes Yes
Barnes et al., 1993 195 Score >1 
(% + intensity)
10 Yes Yes
Silvestrini et al., 1993 256 >5% 6 Yes Yes






André et al., 1997 353 >10% 10 Yes Yes
Rahko et al., 2003 254 Not stated 6 Yes Yes
Studies that showed no association between p53 immunostaining and survival:






Haerslev et al., 1995 490 Any positive
cells
10.5 No No
Rosen et al., 1995 440 >10% 10 No No
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The largest study to date, involving 942 cases of breast cancer with 10 year follow-up,
reported significant correlation between p53 immunostaining and both overall and
disease-free survival (MacGrogan et al., 1995). In a multivariate analysis, p53
immunopositivity was an independent prognostic factor. However, this was of lesser
significance compared to axillary lymph node status, histologic grade and
progesterone receptor status. Few studies examined specifically women with axillary
lymph node negative breast cancer and the results have been inconsistent. Allred et al.
(1993) and Silvestrini et al. (1993) reported significant correlation of p53
immunopositivity and survival outcome. On the contrary, Bosari et al. (1992) and
Rosen et al. (1995) found no such association.  A recent meta-analysis of more than
9,000 breast cancer patients showed that the prognostic value of p53 overexpression is
weak (Barbareschi et al., 2002).
Looking at the summary of data in Table 17, the results of survival analysis were
unlikely to be confounded by sample size, length of follow-up or criteria for p53
immunoreactivity. The differing results highlight the importance to obtain data
pertaining to individual populations to determine the clinical usefulness of p53
immunostaining as a prognostic factor.
In this study of Asian women with a median follow-up of 5 years, p53
immunopositivity was inversely correlated with overall survival. The survival of
patients with p53 positive breast cancers was 52.7% at 5 years compared to 72.3% for
patients with p53 negative tumours (p = 0.046). There appeared to be shorter disease-
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free survival for p53 positive tumours (61.0% vs 73.4%), as well, although this
difference did not achieve statistical significance. Two published series had used the
same criterion for p53 immunopositivity, ie., more than 5% of tumour cells with
nuclear staining. Silvestrini et al. (1993) used the same monoclonal antibody PAb
1801 in 256 cases of invasive breast cancers with a median follow-up of 6 years. He
reported a significant association between p53 immunoexpression and both overall
and disease-free survival. In a multivariate analysis, p53 expression was found to be
an independent prognostic marker. On the contrary, Hanzal et al. (1992) used the
same criterion for p53 immunopositivity albeit with a different antibody, and found




EVALUATION OF p53 GENE IN DUCTAL CARCINOMA IN SITU





It is believed that breast cancer develops through successive stages from normal duct
epithelium to ductal hyperplasia, to atypical ductal hyperplasia, to DCIS, then
invasive ductal carcinoma and eventually metastatic carcinoma. There are data to
suggest that p53 mutations may be important in the development of DCIS (Done et
al., 1998). Done et al. (1998) analysed 8 paired samples of DCIS and invasive ductal
carcinoma, and the same p53 mutation was identified in the DCIS and the
corresponding invasive component. In one case, the mutation was absent in the
corresponding sample of atypical ductal hyperplasia, and in 4 cases, mutations were
absent in the corresponding samples of epithelial hyperplasia. One case-control study
of women with benign breast disease suggested that p53 protein accumulation was
associated with increased risk of subsequent breast cancer (adjusted odds ratio, 2.55;
95% confidence interval, 1.01-6.40) (Rohan et al., 1998). This suggested that p53
mutations played an important role in the clonal selection and progression to breast
carcinoma.
There are limited data documenting p53 mutations in DCIS, especially in the different
histologic subtypes. Two reports have indicated the frequency of p53 mutations to
range from 13-25% in pure DCIS lesions (Chitemerere et al., 1996; Munn et al.,
1996). All other published studies have used p53 protein accumulation as a surrogate
marker of underlying mutations. Such accumulation has been identified in 16-40% of




al., 1994; Eriksson et al., 1994; Zafrani et al., 1994; Bose et al., 1996; Chitemerere et
al., 1996; Munn et al., 1996; Rajan et al., 1997) and reportedly more frequent in the
comedo subtype (Bose et al., 1996; Moreno et al., 1997; Rajan et al., 1997) and high
grade DCIS (Bobrow et al., 1994; Zafrani et al., 1994; Rajan et al., 1997). A recent
study suggests that accumulation of p53 protein is associated with increased risk of
subsequent breast carcinoma in women with benign breast disease (Rohan et al.,
1998).
4.2 OBJECTIVES
The aim of this study was to determine whether p53 mutations are important in the
development of DCIS by examining paired samples of DCIS lesions and their
corresponding normal breast tissue. In addition to determination of the frequency of
mutations, the presence of p53 mutations was correlated with histologic subtypes and
nuclear grade of DCIS lesions. Due to the morphologic heterogeneity of DCIS





4.3 MATERIALS & METHODS
4.3.1 Paired Samples of DCIS and Corresponding Normal Breast Tissue
Formalin-fixed, paraffin-embedded blocks of 28 cases of pure DCIS were used. In
seven cases, the DCIS lesion was estimated to be 1 cm or less while in the remaining
cases, there was extensive disease in that the tumour was present in almost all of the
histological sections submitted. Eight cases were from mastectomy specimens and the
remaining 20 were from wide excision specimens. The study was approved by the
Institution Review Board prior to collection of specimens. 
The histologic subtypes and nuclear grade of all lesions were reviewed and
categorised by a single pathologist (Dr Tan Lee Ki at Memorial Sloan-Kettering
Cancer Center, New York, USA). The lesions were classified according to the growth
pattern as comedo and non-comedo types. The diagnosis of comedo subtype requires
a solid proliferation of large and pleomorphic epithelial cells and the presence of
central necrosis. Non-comedo DCIS encompasses several architectural variants,
including solid, cribriform, micropapillary and papillary DCIS. A three-tier nuclear
grading system was used to designate the nuclear grade of the lesions (The Consensus
Conference Committee, Cancer 1997).
p53 in DCIS
_____________________________________________________________________
High nuclear grade was defined as marked variation in the size and shape of the
nuclei with prominent nucleoli and mitoses (Figure 24).
Fig 24.  Comedo-type
pleomorphic tumour c
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Low nuclear grade was defined as monotonous nuclei with only occasional nucleoli
and mitotic figures (Figure 25). Nuclei that were neither high nor low grade were
classified as intermediate grade.
Fig 25.  Non-comedo or low nuclear grade DCIS growing in a cribriform pattern. The
malignant cells exhibit a monomorphic appearance. Nucleoli show occasional




The distribution of histologic subtypes and nuclear grade of the DCIS lesions are
shown in Table 15. 
Table 15.  Pathologic Characteristics of 30 DCIS Lesions
Characteristics Number (%)
Histologic subtype
     Comedo 13 (43.3)
    Cribriform 7 (23.3)
     Micropapillary 2 (6.7)
     Papillary 4 (13.3)
     Solid 4 (13.3)
Nuclear Grade
     Low grade 12 (40.0)
     Intermediate grade 2 (6.7)
     High grade 16 (53.3)
4.3.2 Tissue Microdissection
DCIS encompasses a variety of architectural patterns and often there is a combination
of different histologic subtypes within a tumour. In addition, most DCIS lesions are
small and contain a significant amount of stromal tissue which could mask genetic
alterations in the tumour. Hence, tissue microdissection is essential in the molecular




subtype and adjacent normal breast tissue were isolated from 10 µm histological
tissue sections as previously described (Youngson et al., 1995). The tissue sections
were prepared on glass slides, baked at 60oC for 30 min, deparaffinised twice with
xylene, rinsed twice with 95% ethanol, stained with haematoxylin and eosin and
subsequently air-dried. Using a light microscope, areas of similar size representing a
specific histologic subtype of DCIS and adjacent normal breast tissue consisting of
stroma and lobular glands were identified for each case. All tissue surrounding the
selected areas was removed with a scalpel. Care was taken to prevent cross-
contamination of normal and carcinoma cells by frequent changes of blade, as well as,
by selecting samples widely separated on the slide. The glass around the selected
areas was wiped clean with 95% ethanol, leaving only the areas of microdissected
tissue on each slide. Each tissue sample was transferred into reaction tubes using a
clean blade.
A total of 30 paired samples of DCIS and corresponding normal breast tissue were
microdissected from the 28 cases; separate foci of cribriform and comedo DCIS were





4.3.3 Mutational Analysis of p53
4.3.3.1 DNA Extraction
Microdissected samples representing specific histologic subtypes were deparaffinised
in xylene and suspended in 50 µl solution containing 10 mM Tris-HCl (pH 8.3), 50
mM KCl, 2.5 mM MgCl2, 0.45% Tween® 20 and 1 mg/ml proteinase K. After
incubation at 56oC for 48h, the samples were boiled for 8-10 min to inactivate the
proteinase K.
4.3.3.2 PCR-SSCP Analysis
In the analysis of 30 DCIS lesions and the corresponding normal breast tissues, exons
5-8 were individually amplified using the same primers as in the analysis of invasive
breast cancers (see 2.3.4.1). Exon 9 was not examined as no genetic alteration in this
exon was identified in the invasive breast cancers. Ten microlitres of genomic DNA
were used for PCR amplification according to a protocol consisting of 35 cycles of
940C for 1 min, annealing temperature (Table 4) for 1 min and 720C for 1 min,
followed by an extension at 720C for 7 min. Five microlitres of each product were re-
amplified in a total volume of 25 µl, using the same primers and amplification
conditions, with incorporation of [α-32P] dCTP (3000 Ci/mmol; Dupont NEN
Research Products). PCR products were diluted in denaturing loading buffer (95%
formamide, 10 mM EDTA [pH 8.0], 0.02% xylene cyanol FF and 0.02%





DNA from two breast carcinoma samples (19T, 34T) and one breast cancer cell line
(MDA-MB-468) found to contain point mutations in p53 served as positive controls
(19T, exon 5; 34T, exon 7; MDA-MD-468, exon 8). One breast carcinoma (4T) which
contained the known polymorphism at codon 213 (CGAÆCGG; ArgÆArg)(Carbone
et al., 1991) was included in the analysis of exon 6 to distinguish band shifts due to
mutations from that due to the polymorphism. Water blanks were included to ensure
the absence of contamination.
Safety precautions undertaken in the handling and disposal of radioactive materials
have been outlined in Section 2.3.8.
4.3.4 Statistical Analysis
p53 mutational status was correlated with histologic subtype and nuclear grade using
Fisher exact test. p values of less than 0.05 were considered to be statistically





4.4.1 p53 Mutational Analysis
All 60 tissue samples were subjected to mutational analysis. Samples that showed
mobility shifts were not sequenced. These lesions were assumed to contain mutations,
as their band patterns were similar to the positive controls. A control sample (breast
carcinoma 4T) harbouring the known polymorphism in exon 6 was included in the
SSCP analysis of exon 6 to distinguish the band pattern of any mutation from that of
this polymorphism.
 Six (20%) of the 30 DCIS samples demonstrated mobility shifts upon SSCP analysis;
three in exon 6, three in exon 7 and one in exon 8. The band shifts in exon 6 for all
three samples were not present in the corresponding normal tissue and were distinct




Fig 26.  Mutational analysis of p53 exon 6 in paired samples of DCIS and normal
breast tissue by SSCP. The papillary DCIS sample marked by an arrow demonstrated
a mobility shift. 4T is a breast carcinoma known to contain the polymorphism
CGAÆCGG (ArgÆArg) at codon 213. Paired samples are indicated by a horizontal




Two of the 6 samples (one cribriform and one comedo) were from the same patient
(Case 7) and both showed a similar band shift in exon 6. Interestingly, the cribriform
subtype demonstrated an additional band shift in exon 7 (Figure 27). None of the
normal breast tissue samples demonstrated conformational shifts.
Fig 27.  Mutational analysis of p53 exon 7 in paired samples of DCIS and normal
breast tissue by SSCP. Separate foci of comedo and cribriform subtypes were
microdissected from Case 7. The cribriform sample (indicated by an arrow)
demonstrated a variant band pattern similar to that of 34T, a breast carcinoma sample
known to contain a point mutation (CGGÆTGG; ArgÆTrp) in exon 7. Paired




4.4.2 Correlation with Histological Subtypes
For the purpose of statistical analysis, the micropapillary, papillary, cribriform and
solid DCIS samples were grouped together as non-comedo DCIS. All non-comedo
lesions were then compared with comedo DCIS as a group. There was no significant
correlation between the presence of p53 mutations and the histologic subtypes
(p=0.67)(Table 16). 
Table 16.  Correlation between p53 Mutations and Histologic Subtypes in 30 Samples
of DCIS
Histologic subtype of DCIS p53 gene
wildtype mutant
Comedo ( n = 13) 11 (84.6%) 2 (15.4%)
Non-comedo ( n = 17) 13 (76.5%) 4 (23.5%)
     micropapillary 1 1
     papillary 3 1
     cribriform 6 1
     solid 3 1
p valuea 0.67




4.4.3 Correlation with Nuclear Grade
Similarly, due to the small number of cases with intermediate nuclear grade, such
lesions were grouped with low grade lesions. Neither was there a difference in the
frequency of p53 mutations among low and high grade lesions (p=0.66)(Table 17).
Among the four non-comedo lesions harbouring mutant p53, two had high nuclear
grade, one intermediate and one was of low grade.
Table 17.  Correlation between p53 Mutations and Nuclear Grade in 30 Samples of
DCIS
Nuclear grade of DCIS p53 gene
wildtype mutant
Low gradea ( n = 14) 12 (85.7%) 2 (14.3%)
High grade ( n = 16) 12 (75.0%) 4 (25.0%)
p valueb 0.66
a includes two lesions of intermediate grade.





4.5.1 Technical Considerations – Tissue Microdissection and Mutational
Analysis
DCIS lesions are morphologically heterogeneous and often there is a combination of
different histologic subtypes within a DCIS lesion. Furthermore, most DCIS lesions
are small and contain a significant amount of stromal tissue. Unless pure populations
of each subtype are obtained in adequate amounts for analysis, not only may genetic
alterations in tumour cells be masked by contaminating stromal tissue, it would also
be difficult to correlate molecular genetic analysis with morphologic subtypes. Hence,
the technique of tissue microdissection was crucial in this study to overcome the
problems of intratumoral heterogeneity and stromal contamination. It provided highly
selected, histologically characterised samples for precise correlative DNA analysis.
While immunohistochemical analysis of the p53 protein has been widely accepted as
a surrogate marker of underlying p53 mutations, stabilisation of the protein and hence
its accumulation could result from non-mutational means as discussed in Section 4.1.
Therefore, in order to determine the stage at which p53 mutations might contribute to





4.5.2 p53 Mutations in DCIS lesions
4.5.2.1 Frequency of p53 Mutations
Mutations within the highly conserved regions of p53 were identified in 20% of our
DCIS samples. This figure is consistent with 2 published reports. Chitemerere et al.
(1996) identified p53 mutations in 4 (13%) of 30 DCIS lesions. But, only one
mutation could be characterised, probably due to normal tissue contamination as the
samples were not microdissected. Munn et al. (1996) reported p53 mutations in 4
(25%) of 16 microdissected DCIS lesions, 3 of which were comedo DCIS and one
was of cribriform subtype. p53 mutational status was not correlated with nuclear
grade. Nonetheless, these and our figures appear to be more conservative than the
incidence of 13-40% reported in immunohistochemical studies.
4.5.2.2 Correlation Between p53 Mutational Status and Histologic Subtype and
Nuclear Grade
Comedo subtype and high nuclear grade have been associated with increased
likelihood of local recurrence and microinvasion in intraductal carcinoma in early
studies (Lagios et al., 1989; Patchefsky et al., 1989; Solin et al., 1993). However,
later studies with longer follow-up have shown a different time course for local
recurrence, but overall no increased risk of recurrence in comedo and high grade
DCIS (Solin et al., 1996). In the interim, many investigators found a significantly
higher frequency of p53 protein accumulation in comedo DCIS (Bose et al., 1996;




et al., 1994; Zafrani et al., 1994; Rajan et al., 1997), leading to the postulation that
DCIS lesions overexpressing p53 proteins were biologically more aggressive. A few
studies did not demonstrate such correlations (Leal et al., 1995; Querzoli et al., 1998).
In the present study, p53 mutations were as frequent, if not more common, in non-
comedo (24%) as in comedo (15%) subtypes. A similar rate of mutations was also
observed among low and high grade DCIS.
4.5.2.3 Possible Genetic Heterogeneity in a DCIS Lesion
In two cases, tissue samples representing two different histologic subtypes of DCIS
were microdissected from the same tumour. In one of these cases, the foci of different
morphology (papillary and cribriform subtypes, both of low nuclear grade) were
negative for p53 mutations. In the second case, the identical p53 mutation in exon 6
was identified in the cribriform and comedo subtypes, both of which were of high
nuclear grade. Interestingly, the cribriform subtype harboured an additional mutation
in exon 7 of p53. This finding is in contrast to that reported by Done et al. (1998) who
identified the same p53 mutations in multiple microdissected samples of DCIS as in
the corresponding invasive component. Although a second mutation in a tumour
suppressor is likely to be a redundant phenomenon, nevertheless, our results suggest





4.5.3 p53 Alterations in Normal Breast Tissue and Benign Breast Disease
p53 mutation was not identified in any of our normal breast tissue samples. Absence
of p53 alterations in normal breast and various benign lesions, including hyperplastic
lesions with or without atypia, has been documented in several studies (Eriksson et
al., 1994; Tsuda et al., 1995; Munn et al., 1996; Done et al., 1998). However, some
groups have demonstrated otherwise. Millikan et al. (1995) found p53 mutations in 5
of 60 (8%) samples of benign breast tissue. In an analysis of 130 usual ductal
hyperplasias, Mommers et al. (1998) identified p53 protein accumulation in 8%. But,
it is unclear if any of these cases were associated with invasive cancer. Overall,
alterations of p53 are rare in normal breast and benign breast lesions compared to
intraductal carcinomas, supporting the hypothesis that such aberrations are important
in the development of DCIS.
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CHAPTER 5
MUTATIONAL AND EXPRESSION ANALYSIS OF
E2F-1 AND E2F-4 IN PRIMARY AND METASTATIC BREAST
CANCER AND CORRESPONDING NORMAL BREAST TISSUES




The E2F family of transcription factors are involved in the regulation of both cell
proliferation and apoptosis, and are able to mediate transcriptional activation and
repression (reviewed in Dyson, 1998). Recently, the member E2F-1 has been
suggested to induce a senescence response in human fibroblasts (Dimri et al., 2000).
Due to their seemingly opposing functions, these factors may act as oncogenes or
tumour suppressors, depending on the cell type and/or experimental conditions.
There is a wealth of data to support the oncogenic and tumour suppressive properties
of E2Fs. The lines of evidence have been presented in the Introduction. Briefly,
ectopic expression of E2F-1 has been shown to induce cell proliferation and
neoplastic transformation in vitro and in vivo (Johnson et al., 1994; Singh et al., 1994;
Pierce et al., 1998). On the contrary, overexpression also results in apoptosis (Qin et
al., 1994; Shan et al., 1994; Wu et al., 1994; Phillips et al., 1997) and mice
nullizygous for E2F-1 showed defects in apoptotic function and increased
tumorigenesis (Field et al., 1996; Yamasaki et al., 1996). Recombinant adenovirus-
mediated overexpression of E2F-1 resulted in apoptosis in breast cancer cell lines
(Hunt et al., 1997). In human malignancies, overexpression of E2F-1 was identified in
63% of human gastric cancers (Suzuki et al., 1999), while its decreased expression
was associated with an increased risk of progression to metastasis and death in
bladder cancer (Rabbani et al, 1999).
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While E2F-1 has been more extensively investigated and characterized, relatively less
is known about E2F-4. E2F-4 can drive cell cycle progression (Beijersbergen et al.,
1994) and cause transformation of mammalian fibroblasts (Beijersbergen et al., 1994;
Ginsberg et al., 1994). E2F-4 transgenic mice also developed tumours sooner and in
greater numbers compared to non-transgenic mice (Wang et al., 200). However, in
vitro and in vivo studies suggest that E2F-4 does not induce apoptosis (DeGregori et
al., 1997; Wang et al., 2000).
There is evidence to suggest that the E2F transcription factors might have an
important role in the p14ARF-hdm2-p53 pathway. E2F-1 overexpression resulted in
induction of p53 (Hiebert et al., 1995; Kowalik et al., 1998) and that accumulation of
p53 could be inhibited by hdm2 (Kowalik et al., 1998). E2F-1 also transactivates the
expression of p14ARF (Bates et al., 1998; Robertson et al., 1998). Recently, it has been
shown that adenovirus-mediated E2F-1 overexpression directly activates expression
of p14ARF, which in turn inhibits hdm2-mediated degradation of p53 and hence results
in the stabilisation of p53 (Itoshima et al., 2000). In addition, sequential transfer of
wild-type p53 and E2F-1 genes in human oesophageal cancer cells resulted in rapid
induction of apoptosis (Itoshima et al., 2000). 




While genetic and expression analyses of the E2Fs have recently been reported in
human malignancies such as bladder and gastrointestinal tumours (Rabbani et al.,
1999; Suzuki et al., 1999), such data pertaining to breast carcinoma are limited. In
view of their diametrically opposite functions and tissue specificity, the goal of this
study was to determine if these transcription factors would act as oncogenes or
tumours suppressors in breast carcinoma. In this study, mutations and expression of
E2F-1 and E2F-4 were investigated in human breast cancer cell lines, and matched
samples of primary and metastatic breast carcinomas.
5.3 MATERIALS AND METHODS
5.3.1 Tissue Samples
Fresh-frozen tissue samples from 11 primary invasive breast carcinomas were
utilised. For each case, corresponding normal breast tissue, primary breast carcinoma
and metastatic carcinoma in lymph nodal tissue were obtained. Normal tissue was
obtained from grossly normal breast tissue away from the primary tumour, while
tumour samples were harvested from the tumour mass and lymph nodes that had been
replaced by tumour. All tissues were procured at the time of surgery and snap frozen
in liquid nitrogen. The study was approved by the Institution Review Board prior to
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collection of tissue samples. Characteristics of the primary breast carcinomas are
summarised in Table 18.
Table 18.  Characteristics of the 11 Primary Breast Carcinomas




Stagea ER Statusb PR Statusc
7 35 Ductal 8.5 III Negative Negative
23 51 Ductal 4.0 II Positive Positive
29 50 Lobular 9.0 III Positive Negative
45 64 Ductal 4.5 II Positive Positive
72 51 Ductal 4.5 II Negative Negative
95 50 Ductal 4.0 III Positive Positive
109 60 Ductal 10.0 III Negative Negative
115 51 Ductal 11.0 IV Positive Positive
131 67 Ductal 8.2 III Negative Negative
135 80 Ductal 3.5 II Positive Negative
164 46 Ductal 7.5 III Positive Positive
a Stage of disease according to AJCC Staging System (Appendix 1).
b Estrogen receptor status
c Progesterone receptor status
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5.3.2 Human Breast Cancer Cell Lines
All cell lines were obtained from the American Type Culture Collection (Rockville,
MD). These included 13 breast cancer cell lines (BT-474, BT-549, Hs 578T, MCF7,
MDA-MB-134, MDA-MB-231, MDA-MB-435, MDA-MB-436, MDA-MB-453,
MDA-MD-468, SK-BR-3, T-47D and ZR-75-1), and two leukaemia cell lines (HEL
and U937). The breast cell lines were grown in DMEM:Ham’s F12 supplemented
with 10% FBS while the leukaemia cell lines were grown in RPMI 1640
supplemented with 10% FBS.
5.3.3 Mutational Analysis of E2F
5.3.3.1 DNA Extraction
As described in 2.3.3.
5.3.3.2 PCR-SSCP Analysis
This was performed for the 11 sets of matched normal breast tissue, primary breast
cancer and metastatic lymph nodal tissue. All primers, except for the primer pair
encompassing the poly(AGC) tract of E2F-4 (previously published; Souza et al.,
1997), were designed based on published sequences of E2F-1 and E2F-4 (Ginsberg et
al., 1994; Neuman et al., 1996) (Table 19).
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Table 19.  Primers for PCR Amplification of E2F-1 and E2F-4
Gene Primer Sequence (5'Æ3') Annealing
Temperature
E2F-1
exon 1 Forward CGTAAAAGTGGCCGGGACTTT 56 oC
Reverse GGGGTCCGTACCGGCGGG
exon 2 Forward CAGAGGCACCCAGCCTTAAG 63 oC
Reverse CAGCCCAAGCTCCATAGGTAC
exon 3 Forward TGCACTGCCAGAGTGGCAGG 64 oC
Reverse GTACCTACAGCCACTGGAT
exon 4 Forward TCCACAGGGGCAGCCACA 64 oC
Reverse TGCTAAGCCTGCCTTCCACA
exon 5 Forward GAAGTCAAAGGTCATGTGGT 60 oC
Reverse AGATCTCACCTCCGAAGAGT
exon 6 Forward AGTTTACCCTGCCTGCTGCT 59 oC
Reverse ACCTTGCTCCAGGCTGAGTA
exon 7 Forward AGAACCGCTGTTGTCCCGGA 60 oC
Reverse CAAGGTGAGCATCTCTGGAA
E2F-4
(AGC)na Forward TGGTCCTCCTGTGTCTGGGTT 57 oC
Reverse AAGGAGGTAGAAGGGTTGG
Rb-binding Forward GAGGAGTTGATGTCCTCAG 58 oC
domain Reverse TCTCAAGCTCTGTAGGGGT
a Primer sequences from Souza et al., 1997.
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Two hundred or 250 ng of DNA were subjected to PCR with 0.2 µl of [α- 32P]dCTP,
10 mM Tris-HCl (pH 8.3; pH 9.5 for E2F-1 exon 1 and pH 10.0 for E2F-1 exon 6),
1.5 mM MgCl2 (1.0 mM for E2F-1 exons 3, 4 and 7, and 2.0 mM for E2F-1 exon 6),
200 µM dNTPs, 20 pmol of each primer and 1U of Taq polymerase in a 20µl reaction
volume. For E2F-1 exons 4 and 6, and E2F-4 (AGC)n the PCR reactions included a
final concentration of 5% DMSO. Amplification conditions consisted of an initial
95°C for 5 min, followed by 30-35 cycles of denaturation (95°C), annealing
(temperatures as shown in Table 8) and extension (72°C), with a final step at 72°C for
5 min in a thermal cycler. PCR products were analysed on a 0.5x or 1.0x (E2F-1 exon
5) MDE gel (FMC BioProducts, Rockland, ME) and visualised by autoradiography. 
5.3.3.3 Direct Sequencing
Samples that demonstrated mobility shifts were either excised from the gel and re-
amplified, or the genomic DNA was amplified using the same set of primers. The
PCR products were electrophoresed on a 2% NuSieve agarose gel, the appropriate
bands excised and DNA fragments extracted using the QIAEX II Gel Extraction Kit
(QIAGEN Inc., Santa Clarita, CA) according to the manufacturer’s protocol. Bi-
directional sequencing was performed with Thermo Sequenase radiolabeled
terminator cycle sequencing kit (United States Biochemical Corporation) according to
the manufacturer’s protocol. Sequences were visualised by autoradiography.
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5.3.3.4 Safety Precautions in Use of Radioactive Materials
The safety precautions undertaken in the handling and disposal of radioactive
materials have been described in Section 2.3.8.
5.3.4 PROTEIN EXPRESSION OF E2F TRANSCIPTION FACTORS
5.3.4.1 Protein Extraction
Tissue samples were diced into small pieces and suspended in cold lysis buffer (50
mM Tris-HCl [pH 8.0], 1 mM EDTA, 0.1% SDS, 0.5% Nonidet-P40 supplemented
with the following protease inhibitors: 100 ug/ml phenylmethylsulfonyl fluoride, 1
ug/ml aprotinin, 1 ug/ml leupeptin and 1 ug/ml pepstatin A) for 30 min at 4oC. The
suspensions were centrifuged at 15,000g for 20 min at 4oC, and the supernatant re-
centrifuged to obtain the total cell lysates in the final supernatant. For the cell lines,
the cultures were rinsed with PBS without calcium and magnesium, and trypsinised.
The cell suspensions were centrifuged at 1000 rpm for 5 min at 4oC, the resultant
pellets resuspended in ice cold PBS and subjected to a repeat centrifugation. The
pellets were then suspended in ice cold lysis buffer and incubated on ice for 20 min.
The lysates were centrifuged to obtain the total cell lysates in the final supernatant.
Protein concentration of all samples was determined by the Pierce BCA protein assay
(Rockland, IL) according to the manufacturer’s protocol.




Fifty µg of proteins were mixed with an equal volume of sample buffer (125 mM Tris
[pH 6.8], 20% gylcerol, 4% SDS, 0.004% bromophenol blue, 10% β-
mercaptoethanol), separated on a 7.5% Tris-HCl precast polyarylamide gel (BioRad,
Hercules, CA) and transferred to Immobilon-P membranes (Millipore, Bedford, MA).
The membranes were blocked with TBS containing 0.1% Tween-20 and 5% dry milk
(blocking solution) for 2 hours at room temperature. The membranes were washed
twice in TBST (100 mM Tris-HCL [pH 7.5], 0.9% NaCl, 0.1% Tween-20) for 10 min
per wash, followed by incubation in 5 ml of blocking solution containing mouse
monoclonal IgG antibody to E2F-1 (KH95; Santa Cruz Biotechnology, Inc., Santa
Cruz, CA) at 1:200 dilution for 1 hour at room temperature, or E2F-4 (D-3; Santa
Cruz Biotechnology, Inc.) at 1:500 dilution for 16 hours at 4oC. The membranes were
washed twice in TBST followed by incubation with a horseradish peroxidase
conjugated sheep anti-mouse IgG antibody at 1:2000 dilution in 5 ml of blocking
solution for an hour at room temperature. After 4 washings with TBST, the
membranes were subjected to ECL Western blotting detection reagents (Amersham
Pharmacia Biotech UK Ltd, Buckinghamshire, England) according to the
manufacturer’s protocol. Membranes were stripped and reprobed with mouse
monoclonal IgG antibody to actin (clone AC-40, Sigma, St Louis, MO) to check for
equal loading of total proteins. Membranes were incubated with stripping solution
(62.5 mM Tris-HCl [pH 6.7], 2% SDS, 100 mM β-mercaptoethanol) at 50oC for 35
min, followed by a rinse with TBST and 3 washings with TBST. Membranes were
checked with ECL detection system to ensure complete removal of antibodies before
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incubation with anti-actin antibody at 1:1000 dilution for 1 hour at room temperature,
incubation with peroxidase conjugated secondary antibody and detection by ECL as
described above.
For the analysis of E2F-1 expression in breast cancer cell lines, the leukaemia cell
lines HEL, which has 8 to 12 copies of the gene and a high level of E2F-1 protein
expression, and U937, with 2 copies of the gene and low level of expression (Saito et
al., 1995), were included in each gel. Protein lysates of matched sets of normal breast
tissue, primary carcinoma, and metastatic nodal tissue of the same case were analysed
on the same gel. Autoradiographic band intensities of the E2Fs were quantitated by
the ChemiImager™ 4000 (Alpha Innotech Corp., San Leandro, CA) and normalised
against the intensity of the corresponding actin band. Band intensities of the human
breast cancer cell lines were compared to those of HEL and U937, whereas, band
intensities of malignant human tissues were compared to that of corresponding normal
breast tissue.
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5.4 RESULTS OF MUTATIONAL ANALYSIS
5.4.1 Primary Breast Cancer and Corresponding Metastatic Nodal Tissues and
Normal Breast Tissues
Eleven sets of human tissues, each set comprising the primary invasive breast cancer
and its corresponding metastatic lymph nodal tissue and normal breast tissue, were
examined for E2F-1 and E2F-4 mutations. The 7 exons of E2F-1 were separately
amplified by PCR and subjected to SSCP analysis. Two cases (18.2%) (Case 45 and
72) demonstrated mobility shifts on SSCP analysis of E2F-1 exon 5. All tissue types
of each case had identical band pattern. The aberrant band pattern of Case 72 is shown
in Figure 28.
Fig 28.  SSCP analysis of E2F-1 exon 5 of matched normal breast tissues (N),
primary breast carcinomas (T) and metastatic lymph nodal tissues (L). All tissue types
of Case 72 showed similar mobility shifts.
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Sequence analysis confirmed the presence of a polymorphism at codon 247
(ACGÆACA; ThrÆThr) in Case 72 (Figure 29). 
Fig 29.  Sequence analysis of E2F-1 exon 5 of the normal breast tissue (N), primary
breast carcinoma (T) and metastatic lymph nodal tissue (L) of Case 72. The
polymorphism comprising a single nucleotide substitution (ACGÆACA; ThrÆThr)
(indicated by an arrow) at codon 247 was identified in all tissue types.
Sequence analysis of the second case (Case 45) showed a polymorphism at codon 276
(GTGÆATG; ValÆMet). No genetic alterations were detected in the other exons of
E2F-1.
For E2F-4, the polyserine tract and pRb-binding domain were separately PCR
amplified. In the SSCP analysis of E2F-4 polyserine tract, three (27%) of the 11 sets
of human tissues (Case 23, 131 and 164) showed mobility shifts (Figure 30A and B).





Fig 30A and B. SSCP analysis of E2F-4 polyserine tract of matched normal breast
tissues (N), primary breast carcinomas (T) and metastatic lymph nodal tissues (L). All
tissue types of Cases 23, 131 and 164 showed mobility shifts.
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An additional AGC repeat in the polyserine tract was identified in all three cases upon
sequencing (Figure 31). 
Fig 31.  Sequence analysis of E2F-4 polyserine tract of the matched normal breast
tissue (N), primary breast carcinoma (T) and metastatic lymph nodal tissue (L) of
Case 23. The addition of an AGC repeat (as indicated) was identified in all tissue
types.
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There was no change observed in the pRB-binding domain of E2F-4 upon SSCP
analysis among the human breast cancers (Figures 32A and B).
(A)
(B)
Fig 32A and B. SSCP analysis of the pRb binding domain of E2F-4 in matched
normal breast tissues (N), primary breast carcinomas (T) and metastatic lymph nodal
tissues (L). No mobility shift was observed.
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5.4.2 Human Breast Cancer Cell Lines
Twelve breast cancer cell lines were subjected to PCR/SSCP analysis for both E2F-1
and E2F-4. One cell line, BT-549 showed a conformational shift on SSCP analysis of
E2F-1 exon 2 (Figure 33), and no aberrations were detected in the remaining exons.
Fig 33.  Mutational analysis of E2F-1 exon 2 by SSCP. The breast cancer cell line
BT-549 demonstrated a mobility shift which was not observed in the tissue samples.
HEL is a leukaemia cell line containing wild-type E2F-1. Matched tissue samples are
indicated by a horizontal line [normal breast tissue (N), primary breast carcinoma (T)
and metastatic lymph nodal tissue (L)].
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Sequencing identified a G:A transition (GCCÆACC; AlaÆThr), a missense
mutation, at codon 102 of E2F-1 in BT-549 (Figure 34).
Fig 34.  Sequence analysis of E2F-1 exon 2 in the breast cancer cell line BT-549. BT-
549 contained a G:A transition (GCCÆACC;  AlaÆThr) at codon 102. The mutated
nucleotide (GÆA) is indicated by an arrow. HEL is a leukaemia cell line representing
the wild-type sequence. 
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In the SSCP analysis of E2F-4 polyserine tract and subsequent sequencing, the
polymorphism comprising an additional AGC repeat tract was also identified in one
breast cancer cell line (MDA-MB-435) (data not shown). There was no band shift
observed in the pRB-binding domain of E2F-4 upon SSCP analysis among the cell
lines (Figure 35). 
Fig 35.  SSCP analysis of the pRb binding domain of E2F-4 in human breast cancer
cell lines. No mobility shift was observed.
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5.5 RESULTS OF EXPRESSION ANALYSIS
5.5.1 Primary Breast Cancer and Corresponding Metastatic Nodal Tissues and
Normal Breast Tissues
The expression of the E2Fs in primary carcinomas and metastatic lymph nodes was
determined by Western blotting. The ratio of the normalised densitometric value of
the tumour tissue to that of its corresponding normal sample was computed. When the
ratio was greater than 1.2 or less than 0.8, the tumour sample was considered to have
expressed the protein at higher or lower level than the normal tissue respectively. Of
the 10 primary tumours, only 2 (20%) overexpressed E2F-1 while the expression level
of one case was similar to that of its corresponding normal tissue. The remaining 7
(70%) tumours demonstrated lower protein levels than the corresponding normal
tissue. Surprisingly, all (10/10; 100%) the metastatic nodal tissues had expression
levels lower than the normal tissue (Figures 36A and B). 





Fig 36A and B.  Western blot analysis of E2F-1 expression in matched samples of
normal breast tissues (N), primary breast carcinomas (T) and metastatic lymph nodal
tissues (L). (A) Compared to the corresponding normal tissue, the expression of E2F-
1 was higher in the primary tumour but reduced in the metastatic nodal tissue of Case
29. (B) In Case 135, the expression level in the primary tumour was similar to that of
the corresponding normal tissue but reduced in the metastatic nodal tissue. In all other
cases, the expression of E2F-1 was lower in both the primary and metastatic tissues.
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Three (30%) of the 10 primary cancers overexpressed E2F-4 while the remaining 7
(70%) expressed the protein at lower levels than the corresponding normal tissue.
Similarly, all (10/10; 100%) the metastatic nodal tissues had expression levels lower
than the normal tissue (Figure 37). 
(A)
(B)
Fig 37A and B.  Western blot analysis of E2F-4 expression in matched samples of
normal breast tissues (N), primary breast carcinomas (T) and metastatic lymph nodal
tissues (L). In Case 29, the expression of E2F-4 was higher in the primary tumour but
lower in the metastatic nodal tissue, compared to the corresponding normal tissue. In
all other cases, the expression level was lower in both the primary and metastatic
tissues.
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5.5.2 Human Breast Cancer Cell Lines
Expression of the E2F-1 protein in the breast cancer cell lines was compared to those
of the leukaemia cell lines, HEL and U937. Overall, 9 (75%) of the 12 cell lines had
normalized densitometric values higher than that of U937, the cell line with a low
level of E2F-1 expression (Saito et al., 1995). Values that were at least equal to or
greater than the mid-point between the values of HEL and U937 were considered to
be representative of a high level of expression. Five cell lines (41.7%) (MCF7, MDA-
MB-231, MDA-MB-435, MDA-MB-453, ZR-75-1) were thus classified as high
expressors of the protein. Three (25%) cell lines (BT-474, Hs 578T, SK-Br-3)
expressed amounts of E2F-1 equivalent to or less than U937 (low expressors). The
remaining four cell lines (BT-549, MDA-MB-436, MDA-MS-468, T-47D) had
expression levels that were higher than U937, but, lower than the midpoint between
that of HEL and U937 (moderate level of expression). Representative western blots
are shown in Figures 38A and B. 
Expression analysis of E2F-4 was not performed for these cell lines because there
were no known controls for comparison.





Fig 38A and B.  Expression of E2F-1 in breast cancer cell lines by western blot
analysis.  The leukaemia cell lines HEL and U937 represent high and low levels of
protein expression respectively (23). (A) BT-474, Hs 578T and SK-BR-3 expressed
low levels of E2F-1 while BT-549 expressed a moderate amount of the protein and
ZR-75-1 had a high expression level similar to that of HEL. (B) MCF7, MDA-MB-
435 and MDA-MB-453 expressed high levels of E2F-1 while moderate level of
expression was observed in MDA-MB-436 and MDA-MB-468.
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5.6 SUMMARY OF RESULTS FOR MATCHED PRIMARY BREAST
CARCINOMA, METASTATIC LYMPH NODAL TISSUES AND
NORMAL BREAST TISSUES
The genetic alterations and expression of E2F-1 and E2F-4 in primary and metastatic
breast carcinomas are summarised in Table 20.
Table 20.  Summary of Mutational and Expression Analyses of E2F-1 and E2F-4 in
11 Matched Primary and Metastatic Breast Carcinomas
Case E2F-1 E2F-4
Number Genea Protein Genea Protein
Tumour Lymph node Tumour Lymph node
7 wt low low wt low low
23 wt high low polym high low
29 wt high low wt high low
45 polym low low wt low low
72 polym low low wt low low
95 wt low low wt low low
109 wt n.d. n.d. wt n.d. n.d.
115 wt low low wt low low
131 wt low low polym low low
135 wt same low wt low low
164 wt low low polym high low
a Represents genetic status of corresponding normal breast, primary breast carcinoma
and metastatic lymph nodal tissue as assessed by PCR-SSCP.
Abbreviations: wt, wild-type; polym, contains polymorphism; n.d., not done.
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5.7 SUMMARY OF RESULTS FOR HUMAN BREAST CANCER CELL
LINES
The genetic alterations and expression of E2F-1 and E2F-4 in human breast cancer
cell lines are summarised in Table 21.
Table 21.  Genetic Alterations and Expression of E2F-1 and E2F-4 in 12 Human
Breast Cancer Cell Lines
Cell line E2F-1 E2F-4
Gene Protein Gene
BT-474 wt low wt
BT-549 mut moderate wt
Hs 578T wt low wt
MCF7 wt high wt
MDA-MB-231 wt high wt
MDA-MB-435 wt high polym
MDA-MB-436 wt moderate wt
MDA-MB-453 wt high wt
MDA-MB-468 wt moderate wt
SK-BR-3 wt low wt
T-47D wt moderate wt
ZR-75-1 wt high wt
Abbreviations: wt, wild-type; mut, mutant; polym, contains polymorphism in
polyserine domain.




5.8.1 E2F-1 and E2F-4 Mutations in Breast Carcinoma
No mutation in either E2F-1 or the polyserine tract and pRb-binding domain of E2F-4
was present in the human tissues. The single nucleotide substitution (GCCÆACC;
AlaÆThr) at codon 102 in exon 2 of E2F-1 was identified in one cell line and this lies
within the cyclin A binding domain of the transcription factor. Although the binding
of cyclin A kinase to E2F-1 has been shown to suppress the DNA-binding activity of
(Krek et al., 1995) and to downregulate the transcription factor in S phase (Krek et
al., 1994), the significance of this mutation is unclear. Two novel polymorphisms in
E2F-1 were identified in the tissue samples, both in exon 5. A different polymorphism
has been reported in bladder carcinoma, but similarly, no mutations were detected
(Rabbani et al., 1999). In this present study, the polymorphism comprising the
addition of one AGC repeat to the polyserine domain of E2F-4 was found in one (8%)
cell line and 3 (27%) of patients. While mutations of the trinucleotide repeats are
relatively common in gastrointestinal tumors with microsatellite instability (Souza et
al., 1997; Ikeda et al., 1998; Kim et al., 1999), such alterations have not been
identified in invasive or preinvasive breast cancers (Walsh et al., 1998; Anbazhagan
et al., 1999). 
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5.8.2 Expression of E2F-1 and E2F-4 in Breast Cancer
The most striking finding in the present study is the lower expression levels of both
E2F-1 and E2F-4 in the majority (70%) of the primary carcinomas compared to their
corresponding normal tissue. More remarkably, all the metastatic cancer in the lymph
nodal tissue expressed the proteins at lower levels than normal tissue. The presence of
polymorphisms did not correlate with expression of the E2Fs. That the E2Fs are
downregulated in the malignant tissues suggests a likely tumour suppressive role in
breast carcinogenesis. It is plausible that E2F-1-induced apoptosis is compromised in
breast malignant cells because an in vitro study suggested that E2F-1 overexpression
lead to apoptosis in breast cancer cell lines (Hunt et al., 1997). Our results further
suggest that these transcription factors may be important in the development of
metastases in breast cancer, a hypothesis that is consistent with the finding in bladder
cancer that decreased expression of E2F-1 is associated with an increased risk of
progression to metastases and death (Rabbani et al., 1999). However, in contrast,
Suzuki et al. (1999) reported the amplification and overexpression of E2F-1 in 63% of
gastric cancers, suggesting that E2F-1 may act as an oncogene in gastrointestinal
carcinoma. All these findings highlight that the net effect of the diametrically opposite
functions of E2Fs is likely to be tissue-specific.
The downregulation of the E2F proteins is likely due to post-transciptional
modification since we did not detect any tumour-specific inactivating mutations in
either E2F-1 or E2F-4. Data from human gastric cancers suggest a combination of
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post-transcriptional and post-translational modification as 40% of cases demonstrated
overexpression of E2F-1 mRNA while 63% overexpressed the protein (Suzuki et al.,
1999). We could not extract sufficient total RNA from the tissue samples to evaluate
mRNA expression. 
It was surprising to find that 42% of the breast cancer cell lines had high levels of
expression while only 25% expressed low levels of the E2F-1 protein. This differs
from the results of the primary and metastatic breast carcinomas. There are two
possible explanations. One, that the definition of low expressors based on the
expression levels of the two leukaemia cell lines are too stringent or perhaps
inappropriate. Of the 18 leukaemia and lymphoblastoid cell lines analysed by Saito et
al. (1995), a spectrum of protein expression levels were observed with U937 being
one of the two lowest expressors. Two, it is possible that immortalised cells in culture
accumulate additional genetic aberrations and evolve over time, and may not
accurately represent the in vivo environment.
5.8.3 Does Downregulation of E2Fs Result in Dysregulation of Apoptosis?
The deregulation of apoptosis may be important in breast tumorigenesis (Bargou et
al., 1995) and there is evidence to suggest that the tumour suppressive potential of
E2F is linked to its apoptotic function. Bargou et al. (1996) demonstrated that
inhibition of endogenous E2F activity in a normal breast epithelial cell line can confer
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resistance to apoptosis without any effect on the rate of cell proliferation and DNA
synthesis, as well as, induce tumour growth in severe combined immunodeficiency
mice. Furthermore, E2F-1 deficient mice have defective apoptotic function and
develop various types of tumours (Field et al., 1996). Although there is no direct
evidence, based on the above findings and ours, it is plausible that the downregulation
of E2F activity results in relative resistance to apoptosis and thereby contributing to
the development and progression of breast cancer. An in vitro study utilising rodent
fibroblasts suggests that among the E2F members, the ability to induce apoptosis is a
function unique to E2F-1 (DeGregori et al., 1997). If this is true for human breast
tissue, the lower expression of E2F-4 in primary and metastatic breast cancers as
observed in this study warrants further investigation as this finding is counterintuitive








The significant findings of the four studies are summarised in the following sections.
6.1.1 Genetic Alteration of p14ARF-hdm2-p53 Regulatory Pathway In Breast
Cancer
Genetic alterations in the various components of this cell cycle pathway were
identified in 25% of the primary breast cancers and 64% of the human breast cell
lines. p53 mutations were the predominant aberrations, occurring in 19% and 50% of
the tumours and cell lines, respectively. Although p14ARF mutations and hdm2
amplification are potential mechanisms of p53 inactivation, these events were
relatively uncommon in invasive breast cancers.
Deregulation of this pathway could occur via other mechanisms. The β transcript of
p14ARF was expressed in all tissue samples, suggesting that p14ARF activity could be
regulated by post-translational modification. Data on expression of the p14ARF protein
in normal and malignant breast tissues are essential to further determine its role in
breast carcinogenesis. Amplification of hdm2 was observed in only 7% of the primary
tumours in this study, consistent with published reports. Similar to p14ARF, post-





6.1.2 Immunohistochemical Analysis of p53 in Invasive Breast Cancer
To date, it is still controversial as to whether p53 alteration is a molecular marker of
prognostic significance in breast cancer. While there is general agreement that p53
protein accumulation correlates with adverse clinicopathologic factors, current data
suggest that p53 immunopositivity is at most a weak prognostic indicator.
In this study of 105 Asian women with breast cancer, p53 immunopositivity was
detected in 35% of the primary invasive cancers. It was significantly correlated with
poor histologic grade, but not with stage of disease at presentation. At a median
follow-up of 5 years, patients with p53 positive tumours experienced significantly
shorter overall survival while p53 immunostaining did not influence disease-free
survival. These results need to be validated by a larger series with a longer follow-up.
A much larger number of cases is also required to allow statistical analysis based on
axillary lymph nodal status.
6.1.3 p53 Mutations in DCIS and Normal Breast Tissues
p53 mutations are relatively common in DCIS lesions, present in 20% of the cases.
The absence of mutations in the corresponding normal breast tissue supports the
hypothesis that such aberrations are important in the development of DCIS. There was




DCIS. p53 mutations were also as frequent among lesions with high nuclear as in low
grade DCIS lesions. The prognostic value of these alterations in DCIS needs to be
determined by correlating abnormalities of p53 with the clinical outcome of this
histologically and biologically heterogeneous disease as measured by local recurrence
and eventual development of invasive disease. 
6.1.4 E2F-1 and E2F-4 in Matched Malignant and Normal Breast Tissues
Alterations in E2Fs appear to be more prevalent that those of p53. The most
significant finding in this study was the reduced expression of both transcription
factors in the malignant tissues compared to the corresponding normal breast tissues.
Majority (70%) of the primary invasive cancers expressed lower protein levels of
E2F-1 and E2F-4, and all the metastatic lymph nodal tissues demonstrated lower
protein levels of both factors. This marked downregulation in tumour tissues suggests
a likely tumour suppressive role for the E2Fs in breast carcinogenesis and that they
may be important in the development of metastasis.
The tumour suppressive property of E2F-1 could be attributed to its ability to induce
apoptosis. That recombinant adenovirus-mediated overexpression of E2F-1 in breast
cancer cell lines resulted in apoptosis (Hunt et al., 1997) suggests a potential
therapeutic target in the treatment of breast cancer. The lower expression levels of




properties and does not have the ability to induce apoptosis (DeGregori et al., 1997;
Wang et al., 2000). Additional work is necessary to further elucidate the mechanisms
involved in the functions of E2F downregulation in breast cancer.
6.1.5 Concluding Remarks
The results of the various studies support the hypothesis that deregulation of the
p14ARF-hdm2-p53 pathway and the transcription factors, E2F-1 and E2F-4, are likely
to play significant roles in breast carcinogenesis.
6.2 FUTURE RESEARCH
There are several areas in which further work might add to understanding the
significance and contribution of the various genes in breast carcinogenesis:
1) p53 mutations should be evaluated in matched samples of normal breast
tissue, ductal hyperplasia, atypical ductal hyperplasia and DCIS lesions to
determine the exact stage at which these mutations are critical.
2) It is still worthwhile to pursue p53 immunopositivity as a potential
prognostic indicator as the current clinical parameters used are not adequate
to identify the subset of women who have node negative disease but are at




immunopositivity is associated with shorter overall survival in Asian women
with breast cancer, a much larger series with longer follow-up is necessary,
with stratification based on axillary nodal status.
3) Similarly, the prognostic significance of p53 mutations in DCIS should be
determined by correlating the mutational status with the clinical outcome as
measured by local recurrence and eventual development of invasive disease.
4) Although no mutation in or altered mRNA expression of p14ARF was present
in the primary breast carcinomas, evaluation of p14ARF mRNA and protein
expression should be performed in matched normal and primary cancers to
establish if these are uncoupled.
5) The downregulation of E2F proteins in primary and metastatic breast
cancers needs to be validated by a larger series as only 10 cases were
analysed in the present study. In addition, both mRNA and protein
expression should be examined to determine the mechanism of E2F protein
downregulation.
6) Whether E2F-1-induced apoptosis is dependent on p53 or not is unclear in
breast carcinoma. It would be interesting to determine the p53 status in
tumours with and without altered expression levels of E2Fs and to elucidate






Allred DC, Clark GM, Elledge R, Faqua SAW, Brown RW, Chamness GC, Osborne
CK, McGuire WL. Association of p53 protein expression with tumour cell
proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer
Inst 1993; 85:200-6.
André S, Pereira H, Nogueira M, Cardoso P, Bernardo M, Meneses e Sousa J, Soares
J. p53 overexpression is a prognostic indicator in poorly differentiated, node negative
and T1/T2 invasive ductal breast cancer patients. Breast 1997; 6:194-201.
Anbazhagan R, Fujii H, Gabrielson E. Microsatellite instability in uncommon in
breast cancer. Clin Cancer Res 1999; 5:839-44.
Anelli A, Anelli TFM, Youngson B, Rosen PP, Borgen PI. Mutations in the p53 gene
in male breast cancer. Cancer 1995; 75:2233-8.
Asschert JGW, Vellenga E, J, de Jong S, de Vries EGE. Mutual interactions between
p53 and growth factors in cancer. Anticancer Res 1998; 18:1713-26.
Baas IO, Mulder J-WR, Offerhaus JA, Volgelstein B, Hamilton SR. An evaluation of
six antibodies for immunohistochemistry of mutant p53 gene product in archival
colorectal neoplasms. J Pathol 1994;172:5-12.
Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, vanTuinen
P, Ledbetter DH, Barker DF, Nakamura Y. Chromosome 17 deletions and p53 gene
mutations in colorectal carcinomas. Science 1989; 244:217-21.
Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wildtype p53
activity. EMBO J 1993; 12:461-8.
Barbareschi M. Prognostic value of the immunohistochemical expression of p53 in
breast carcinomas: a review of the literature involving over 9,000 patients. Appl
Immunohistochem 2002; 4:106-16.
Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagener C, Kallinich B, Royer
HD, Dörken B. Expression of the bcl-2 gene family in normal and malignant breast
tissue: low bax-a expression in tumor cells correlate with resistance towards
apoptosis. Int J Cancer 1995; 60:854-9.
Bargou RC, Wagener C, Bommert K, Arnold W, Daniel PT, Mapara MY, Grinstein
E, Royer HD, Dörken B. Blocking of transcription factor E2F/DP by dominant-
negative mutants in a normal breast epithelial cell line efficiently inhibits apoptosis
and induces growth in SCID mice. J Exp Med 1996; 183:1205-13.
Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR. Immunohistochemical
detection of p53 protein in mammary carcinoma: an important new independent




Bartek J, Iggo R, Lane DP. Genetic and immunohistochemical analysis of mutant p53
in human breast cancer cell lines. Oncogene 1990; 5:893-9.
Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, Vousden KH. p14ARF
links the tumour suppressors RB and p53. Nature 1998; 395:124-5.
Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ (eds): American Joint Committee
on Cancer: Manual for Staging Cancer. 4th edn, JB Lippincott, Philadelphia, 1992.
Beck T, Weller EE, Weikel W, Brumm C, Wilkens C, Knapstein PG. Usefulness of
immunohistochemical staining for p53 in the prognosis of breast carcinomas:
correlations with established prognosis parameters and with the proliferation marker,
MIB-1. Gynecol Oncol 1995; 57:95-104.
Beijersbergen RL, Kerkhoven RM, Zhu L, Carlee L, Voohoeve PM, Bernards R. E2F-
4, a new member of the E2F gene family, has oncogenic activity and associates with
p107 in vivo. Genes Dev 1994; 8:2680-90.
Bergh J, Norberg T, Sjögren S, Lindgren A, Holmberg L. Complete sequencing of the
p53 gene provides prognostic information in breast cancer patients, particularly in
relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995; 1:1029-34. 
Bertheau P, Cazals-Hatem D, Meignin V, de Roquancourt A, Vérola O, Lesourd A,
Sene C, Brocheriou C, Janin A. Variability of immunohistochemical reactivity on
stored paraffin slides. J Clin Pathol 1998;51:370-4.
Bhargava V, Thor A, Deng G, Ljung B, Moore II HD, Waldman F, Benz C, Goodson
W III, Mayall B, Chew K. The association of p53 immunopositivity with tumour
proliferation and other prognostic indicators in breast cancer. Mod Pathol 1994;
7:361-8.
Bobrow LG, Happerfield LC, Gregory WM, Springall RD, Millis RR. The
classification of ductal carcinoma in situ and its association with biological markers.
Semin Diagn Pathol 1994; 11:199-207.
Boddy MN, Freemont PS, Borden KL. The p53-associated protein MDM2 contains a
newly characterized zinc-binding domain called the RING finger. Trends Biochem Sci
1994; 19:198-9.
Bose S, Lesser ML, Norton L, Rosen PP. Immunophenotype of intraductal carcinoma.
Arch Pathol Lab Med 1996; 120:81-5.
Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T.





Bueso-Ramos CE, Yang Y, Deleon E, McCown P, Stass SA, Albitar M. The human
MDM2 oncogene is overexpressed in leukemias. Blood 1993; 82:2617-23.
Bueso-Ramos CE, Manshouri T, Haidar MA, Yang Y, McCown P, Ordonez N,
Glassman A, Sneige N, Albitar M. Abnormal expression of MDM-2 in breast
carcinomas. Breast Cancer Res Treat 1996; 73:179-88.
Bourdon JC, Deguin-Chambon V, Lelong JC, Dessen P, May P, Debuire B, May E.
Further characterisation of the p53 responsive element - identification of new
candidate genes for transactivation by p53. Oncogene 1997; 14:85-94.
Busmanis I, Feleppa F, Jones A, McGrath KM, Reed R, Collins J, Russell I, Begley
CG. Analysis of cerbB2 expression using a panel of 6 commercially available
antibodies. Pathol 1994; 26:261-7.
Cailleau R, Mackey B, Young RK, Reeves WJ Jr. Tissue culture studies on pleural
effusions from breast carcinoma patients. Cancer Res 1974; 34:801-9.
Callahan R. p53 mutations, another breast cancer prognostic factor. J Natl Cancer Inst
1992; 84:826-7.
Carbone D, Chiba T, Mitsudomi T. Polymorphism at codon 213 within the p53 gene.
Oncogene 1991; 6:1691-2.
Chen CY, Oliner JD, Zhan Q, Fornace AJ, Vogelstein B, Kastan MB. Interactions
between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl
Acad Sci USA 1994; 91: 2684-8.
Chen LC, Neubauer A, Kurisu W, Waldman FM, Ljung B, Goodson W, Goldman ES,
Moore D, Balazs M, Liu E, Mayall BH, Smith HS. Loss of heterozygosity on the
short arm of chromosome 17 is associated with high proliferative capacity and DNA
aneuploidy in primary breast cancer. Proc Natl Acad Sci USA 1991; 88:3847-51.
Chen J, Wu X, Lin J, Levine AJ. mdm2 inhibits the G1 arrest and apoptosis functions
of the p53 tumour suppressor protein. Mol Cell Biol 1996; 16:2445-52.
Chia KS, Seow A, Lee HP, Shanmugaratnam K. Trends in cancer incidence in
Singapore 1968-1992. Singapore Cancer Registry Report No. 4, 1996.
Chia KS, Seow A, Lee HP, Shanmugaratnam K. Cancer incidence in Singapore 1993-
1997. Singapore Cancer Registry Report No. 5, 2000.
Chitemerere M, Anderson TI, Holm R, Karlsen F, Borresen A-L, Nesland JM. TP53
alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast.




Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM,
Marechal V, Chen J, Brennan MF, Levine AJ. Molecular abnormalities of mdm2 and
p53 genes in adult soft tissue sarcomas. Cancer Res 1994; 54:794-9.
Cuny M, Kramar A, Courgal F, Johannsdottir V, Iacopetta B, Fontaine H, Grenier J,
Culine S, Theillet C. Relating genotype and phenotype in breast cancer: an analysis of
the prognostic significance of amplification at eight different genes or loci and of p53
mutations. Cancer Res 2000; 60:1077-83.
Courjal F, Rodriguez C, Louason G, Speiser P, Katsaros D, Tanner MM, Zeillinger R,
Theillet C: DNA amplifications at 20q13 and MDM2 define distinct subsets of
evolved breast and ovarian tumours. Br J Cancer 1996; 74:1984-9.
Davidoff AM, Kerns B-JM, Iglehart JD, Marks JR. Maintenance of p53 alterations
throughout breast cancer progression. Cancer Res 1991a; 51:2605-10.
Davidoff  AM, Humphrey PA, Iglehart JD, Marks JR. Genetic basis for p53
overexpression in human breast cancer. Proc Natl Acad Sci USA 1991b; 88: 5006-10.
DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR. Distinct roles for E2F proteins
in cell growth control and apoptosis. Proc Natl Acad Sci USA 1997; 94:7245-50.
Dickson RB, Lippman ME. Oncogenes, suppressor genes, and signal transduction. In:
Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the breast, 2nd
ed, Lippincott Williams & Wilkins, Philadelphia, 2000: 281-302.
Dimri GP, Itahana K, Acosta M, Campisi J. Regulation of a senescence checkpoint
response by the E2F1 transcription factor and p14ARF tumor suppressor. Mol Cell Biol
2000; 20:273-85.
Done SJ, Arneson NCR, Özçelik H, Redston M, Andrulis IL. p53 mutations in
mammary ductal carcinoma in situ but not in epithelial hyperplasias. Cancer Res
1998; 58:785-9.
Donehower LA, Bradley A. The tumour suppressor p53. Biochem Biophys Acta 1993;
1155:181-205.
Dunn JM, Hastrich DJ, Webb JCJ, Maitland NJ, Farndon JR. Correlation between p53
mutations and antibody staining in breast carcinoma. Br J Surg 1993; 80:1410-2.
Dyson N. The regulation of E2F by pRb-family proteins. Genes Dev 1998; 12:2245-
62.
Eeles RA, Bartkova J, Lane DP, Bartek J. The role of TP53 in breast cancer




El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a
consensus binding site for p53. Nat Genet 1992; 1:45-9.
El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D,
Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor
suppression. Cell 1993; 75:817-25.
El-Deiry WS, Harper JW, O’Connor PM, Velsulescu VE, Canman CE, Jackman J,
Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB,
Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B. WAF1/CIP1 is induced in p53-
mediated G1 arrest and apoptosis. Cancer Res 1994; 54:1169-74.
Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M. Wild-type p53 can
inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 1989; 86:8763-
7.
Elledge RM, Fuqua SAW, Clark GM, Pujol P, Allred C, McGuire WL. Prognostic
significance of p53 gene alterations in node-negative breast cancer. Breast Cancer
Res Treat 1993; 26: 225-35. 
Elledge RM, Allred DG. The p53 tumour suppressor gene in breast cancer. Breast
Cancer Res Treat 1994; 32:39-47.
Engel LW and Young NA. Human breast cancer cells in continuous culture: a review.
Cancer Res, 1978; 38:4327-39.
Epstein R. Drug-induced DNA damage and tumor chemosensitivity. J Clin Oncol
1990; 8:2062-84.
Eriksson ET, Schimmelpenning H, Aspenblad U, Zetterberg A, Auer GU.
Immunohistochemical expression of the mutant p53 protein and nuclear DNA content
during the transition from benign to malignant breast disease. Hum Pathol 1994;
25:1228-33.
Esteve A, Lehman T, Jiang W, Weinstein IB, Harris CC, Ruol A, Peracchia A,
Montesano R, Hollstein M. Correlation of p53 mutations with epidermal growth
factor receptor overexpression and absence of mdm2 amplification in human
esophageal carcinomas. Mol Carcinogen 1993; 8:306-11.
Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with
enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J
1991; 10:1565-9.
Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C.Wild-type p53




Faverly DR. Burgers L, Bult P, Holland. Three-dimensional imaging of the mammary
ductal carcinoma in situ: clinical implications. Semin Diagn Pathol 1994; 11:193-8.
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;
61:759.
Ferreira R, Magnaghi-Jaulin L, Rpbin P, Harel-Bellan A, Trouche D. The three
members of the pocket proteins family share the ability to repress E2F activity
through recruitment of a histone deacetylase. Proc Natl Acad Sci USA 1998:
95;10493-8.
Field SJ, Tsai F-Y, Kuo F, Zubiaga AM, Kaelin WG Jr, Livingston SH, Orkin SH,
Greenberg ME. E2F-1 functions in mice to promote apoptosis and suppress
proliferation. Cell 1996; 85:549-61.
Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of
transformation. Cell 1989; 57:1083-93.
Finlay C. The mdm-2 oncogene can overcome wild-type p53 suppression of
transformed cell growth. Mol Cell Biol 1993; 13:301-6.
Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER. Relation of number of
positive axillary lymph nodes to the prognosis of patients with primary breast cancer.
Cancer 1983; 52:1551-6.
Fisher CJ, Gillett CE, Vojtesek B, Bernes, Millis RR. Problems with p53
immunohistochemical staining: the effect of fixation and variation in the methods of
evaluation. Br J Cancer 1994;69:26-31.
Fisher ER, Gregorio R, Fisher B , Redmond C, Vellios F, Sommers SC. The
pathology of invasive breast cancer. A syllabus derived from findings of the National
Surgical Adjuvant Breast Project (Protocol No. 4). Cancer 1975; 36:1.
Fitzgerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H,
O’Neill E, Koh J, Finkelstein DM, Isselbacher KJ, Sober AJ, Haber DA. Prevalence
of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a
clinic-based population. Proc Natl Acad Sci USA 1996; 93:8541-5.
Friedrichs K, Gluba S, Eidtmann H, Jonat W. Overexpression of p53 and prognosis in
breast cancer. Cancer 1993; 72:3641-7.
Fritsche M, Haessler C, Bradner G. Induction of nuclear accumulation of the tumor
suppressor protein p53 by DNA damaging agents. Oncogene 1993; 8:307-18.
Frye RA, Benz CC, Liu E. Detection of amplified oncogenes by differential




Foulds L. The natural history of cancer. J Chronic Dis 1958; 8:2.
Foulkes WD, Stamp GW, Afzal S, Lalani N, Mcfarlane CP, Trowsdale J, Campbell
IG. MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation
status. Br J Cancer 1995; 72:883-8.
Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT,
Knowles DM, Dalla-Favera R. p53 mutations in human lymphoid malignancies:
association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl
Acad Sci USA 1991; 88:5413-7.
Gannon JV, Lane DP. Protein synthesis required anchoring a mutant p53 protein
which is temperature-sensitive for nuclear transport. Nature 1991; 349:802-6.
Gazzeri S, Valle VD, Chaussade L, Brambilla C, Larsen CJ, Brambilla E. The human
p19ARF protein encoded by the β transcript of the p16INK4a gene is frequently lost in
small cell lung cancer. Cancer Res 1998; 58:3926-31.
Ginsberg D, Vairo G, Chittenden T, Xiao Z-X, Xu G, Wydner KL, DeCaprio JA,
Lawrence JB, Livingston DM. E2F-4, a new member of the E2F transcription factor
family, interacts with p107. Genes Dev 1994; 8:2665-79.
Gorgoulis VG, Zoumpourlis V, Rassidakis GZ, Karameris A, Rassidakis AN,
Spandidos DA, Kittas C. A molecular and immunohistochemical study of the MDM2
protein isoforms and p53 gene product in bronchogenic carcinoma. J Pathol 1996;
180:129-37.
Gottlieb TM, Oren M. p53 in growth control and neoplasia. Biochim Biophys Acta
1996; 1287:77-102.
Hackett AJ, Smith HS, Springer EL, Owens RB, Nelson-Rees WA, Riggs JL, Gardner
MB. Two synergeic cell lines from human breast tissue: the aneuploid mammary
epithelial (Hs578T) and diploid myoepithelial (Hs578Bst) cell lines, J Natl Cancer
Inst 1997; 58:1795-806.
Haerslev T, Jacobsen GK. An immunohistochemical study of p53 with correlations to
histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and
prognosis. Hum Pathol 1995; 26:295-301.
Haffner R, Oren M. Biochemical properties and biological effects of p53. Curr Opin
Genet Dev 1995; 5:84-90. 
Hanzal E, Gotsch G, Kohlberger P, Dadak C, Miechowiecka N, Breitenecker G.
Immunohistochemical detection of mutant p53-suppressor gene product in patients





Harper JW, Elledge SJ, Keyomarse K, Dynlacht B, Tsai L-H, Zhang P, Dobrowolski
S, Bai C, Connel-Crowley L, Swindell E, Fox MP, Wei N. Inhibition of cyclin-
dependent kinases by p21. Mol Biol Cell 1995; 6:387-400.
Hartmann A, Blaszyk H, McGovern RM, Schroeder JJ, Cunningham J, De Vries
EMG, Kovach JS, Sommer SS. p53 gene mutations inside and outside of exons 5 – 8:
the patterns differ in breast and other cancers. Oncogene 1995; 10:681-8.
Haupt Y, Barak Y, Oren M. Cell type-specific inhibition of p53-mediated apoptosis
by mdm2. EMBO J 1996; 15:1596-1606.
Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53.
Nature 1997; 387:296-9.
Hiebert SW, Packham G, Strom DK, Haffner R, Oren M, Zambetti G, Clveland JL.
E2F-1: DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol Cell
Biol 1995; 15:6864-74.
Higashiyama M, Doi O, Kodama K, Yokouchi H, Kasugai T, Ishiguro S, Takami K,
Nakayama T, Nishisho I. MDM2 gene amplification and expression in non-small cell
lung cancer: immunohistochemical expression of its protein is a favourable prognostic
marker in patients without p53 protein accumulation. Br J Cancer 1997; 75:1302-8.
Hijmans EM, Voorhoeve PM, Beijersbergen RL, Van’T Veer LJ, Bernards R. E2F-5,
a new E2F family member that interacts with p130 in vivo. Mol Cell Biol 1995;
15:3082-9.
Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ, Zafrani B.
Ductal carcinoma in situ: A proposal for a new classification. Semin Diagn Pathol
1994; 11:167-80.
Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers.
Science 1991; 253:49-53.
Holmberg C, Helin K, Sehested M, Karlstrom O. E2F-1-induced p53-independent
apoptosis in transgenic mice. Oncogene 1998; 17:143-55.
Hsieh J-K, Fredersdorf S, Kouzarides T, Martin K, Lu X. E2F-1 induced apoptosis
requires DNA binding but not transactivation and is inhibited by the retinoblastoma
protein through direct interaction. Genes Dev 1997; 11:1840-52.
Hunt KK, Deng J, Liu T-J, Wilson-Heiner M, Swisher SG, Clayman G, Hung M-C.
Adenovirus-mediated overexpression of the transcriptions factor E2F-1 induces
apoptosis in human breast and ovarian carcinoma cell lines and does not require p53.




Hupp TR. Regulation of p53 protein function through alterations in protein-folding
pathways. Cell Mol Life Sci 1999; 55:88-95.
Hurlimann J. Prognostic value of p53 protein expression in breast carcinomas. Pathol
Res Pract 1993; 189:996-1003.
Hurlimann J, Chaubert P, Benhattar J. p53 gene alterations and p53 protein
accumulation in infiltrating ductal breast carcinomas: correlation between
immunohistochemical and molecular biology techniques. Mod Pathol 1994; 7:423-8.
Ikeda M-A, Jokoi L, Nevins J. A unique role for the Rb protein in controlling E2F
accumulation during cell growth and differentiation. Proc Natl Acad Sci USA 1996;
93:3215-20.
Ikeda M, Orimo H, Moriyama H, Nakajima E, Matsubara N, Mibu R, Tanaka N,
Shimada T, Kimura A, Shimizu K. Close correlation between mutations of E2F-4 and
hMSH3 genes in colorectal cancers with microsatellite instability. Cancer Res 1998;
58:594-8.
Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, Flores ER, Tsai KY,
Jacks T, Vousden KH, Kaelin Jr WG. Role for the p53 homologue p73 in E2F-1-
induced apoptosis. Nature 2000; 407:645-8.
Isobe M, Emanuel BS, Givol D, Oren M, Croce CM. Localization of gene for human
p53 tumour antigen on band 17p13. Nature 1986; 320:84-5.
Isola J, Visakorpi T, Holli K, Kallioniemi O. Association of overexpression of tumour
suppressor protein p53 with rapid cell proliferation and poor prognosis in node-
negative breast cancer patients. J Natl Cancer Inst 1992; 84:1109-13.
Itoshima T, Fujiwara T, Waku T, Shao J, Kataoka M, Yarbrough WG, Liu T-J, Roth
JA, Tanaka N, Kodama. Induction of apoptosis in human oesophageal cancer cells by
sequential transfer of the wild-type p53 and E2F-1 genes: involvement of p53
accumulation via ARF-mediated MDM2 down-regulation. Cancer Res 2000; 6:2851-
9.
Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, Mukai K,
Hirohashi S. Nuclear p53 immunoreaction associated with poor prognosis of breast
cancer. Jpn J Cancer Res 1991; 82:835-40.
Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ. Loss of tumor marker-





Janus F, Albrechtsen N, Dornreiter I, Wiesmuller L, Grosse F, Deppert W. The dual
role model for p53 in maintaining genomic integrity. Cell Mol Life Sci 1999; 55:12-
27.
Joensuu H and Toikkanen S. Identification of subgroups with favourable prognosis in
breast cancer. Acta Oncol 1992; 31:293-301.
Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor
E2F-1 induced quiescent cells to enter S phase. Nature 1993; 365:349-52.
Johnson DG, Cress WD, Jakoi L, Nevins JR. Oncogenic capacity of the E2F1 gene.
Proc Natl Acad Sci USA 1994; 91:12823-7.
Kamb A, Gruis NA, Weaver-Feldhaus J, Liu J, Harshman K, Tavtigian SV, Stocjert
E, Day RS, Johnson BE, Skolnick MH. A cell cycle regulator potentially involved in
genesis of many tumour types. Science 1994; 265:436-40.
Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G,
Sherr CJ. Tumor suppression at the mouse INK4a locus mediated by the alternative
reading frame product p19ARF. Cell 1997; 91:649-59.
Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functinoal and
physical interactions of the ARF tumour suppressor with p53 and Mdm2. Proc Natl
Acad Sci USA 1998; 95:8292-7.
Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of
p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51:6304-11.
Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS,
Vogelstein B, Fornace AJ Jr. A mammalian cell cycle checkpoint pathway utilising
p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71:587-97.
Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein
B.Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992;
256:827-30.
Khan SH, Motitsugu J, Wahl GM. Differential requirement for p19ARF in the p53-
dependent arrest induced by DNA damage, microtubule disruption, and
ribonucleotide depletion. Proc Natl Acad Sci USA 2000; 97:3266-71.
Kim JJ, Baek MJ, Kim L, Kim N-G, Lee YC, Song SY, Noh SH, Kim H.
Accumulated frameshift mutations at coding nucleotide repeats during the progresion
of gastric carcinoma with microsatellite instability. Lab Invest 1999; 79:1113-20.
Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS. Mutation




cancer can have important prognostic value. Proc Natl Acad Sci USA 1996; 93:1093-
6.
Kowalik TF, DeGregori J, Swchwarz JK, Nevins JR. E2F1 overexpression in
quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J
Virol 1995; 69:2491-500.
Kowalik TF, De Gregori J, Leone G, Jakoi L, Nevins JR. E2F-1-specific induction of
apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ
1998; 9:113-8.
Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl
Acad Sci USA 1971; 68:820.
Krek W, Ewen ME, Shirodkar S, Arany Z, Kaelin WG Jr, Livingston DM. Negative
regulation of the growth-promoting transcription factor E2F-1 by a stably bound
cyclin A-dependent protein kinase. Cell 1994; 78:161-72.
Krek W, Xu G, Livingston DM. Cyclin A-kinase regulation of E2F-1 DNA binding
function underlies suppression of an S-phase checkpoint. Cell 1995; 83:1149-58.
Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature
1997; 387:299-303.
Lagios MD, Frederick R, Margolin MD, Westdahl PR, Rose MR. Mammographically
detected duct carcinoma in situ. Frequency of local recurrence following tylectomy
and prognostic effect of nuclear grade on local recurrence. Cancer 1989; 63:618-24.
Lam EW, La Thangue NB. DP and E2F proteins: coordinating transcription with cell
cycle progression. Curr Opin Cell Biol 1994; 6:859-66.
Landers JE, Haines DS, Strauss JF III, George DL. Enhanced translation: a novel
mechanism of mdm2 oncogene overexpression identified in human tumor cells.
Oncogene 1994; 9:2745-50.
Lane DP, Crawford LV. T-antigen is bound to host protein in SV40-transformed cells.
Nature 1979; 278:261-3.
Lane DP, Benchimol S. p53: oncogene or antioncogene? Genes Dev 1990; 4:1-8.
Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358:15-6.
Leach FS, Tokino P, Meltzer M, Burrell JD, Oliner S, Smith DE, Hill D, Sidransky
KW, Kinzler K, Vogelstein B. p53 mutation and MDM2 amplification in human soft




Leal CB, Schmitt FC, Bento MJ, Maia NC, Lopes CS. Ductal carcinoma in situ of the
breast: histologic categorization and its relationship to ploidy and
immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein.
Cancer 1995; 75:2123-31.
Leng P, Brown DR, Shivakumar CV, Deb S, Deb SP. N-terminal 130 amino acids of
MDM2 are sufficient to inhibit p53-mediated transcriptional activation. Oncogene
1995; 10:1275-82.
Levine AJ. The p53 protein and its interactions with the oncogene products of the
small DNA tumour viruses. Virology 1990; 177:419-26.
Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-
31.
Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumour antigen
in SV40 transformed cells. Cell 1979; 17:43-52.
Lipponen P, Ji H, Aaltomaa S, Syrjanen S, Syrjanen K. p53 protein expression n
breast cancer as related to histopathological characteristics and prognosis. Int J
Cancer 1993; 55:51-6.
Lohmann D, Ruhri C, Schmitt M, Graeff H, Hofler H. Accumulation of p53 protein as
an indicator for p53 gene mutations in breast cancer. Occurrence of false-positives
and false-negatives. Diagn Mol Pathol 1993; 2:36-41.
Luo RX, Postigo AA, Dean DC. Rb interacts with histone deacetylase to repress
transcription. Cell 1998; 92:463-73.
MacGrogan G, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre J-
M. Prognostic value of p53 in breast invasive ductal carcinoma: an
immunohistochemical study of 942 cases. Breast Cancer Res Treat 1995; 36:71-81.
Maemura M, Akiyama SK, Woods VL Jr, Dickson RB. Expression and ligand
binding of α2β1 integrin on breast carcinoma cells. Clin Exp Metastatsis 1995;
13:223-35.
Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP,
Troalen F, Trouche D, Harel-Bellan A. Retinoblastoma protein represses transcription
by recruiting a histone deacetylase. Nature 1998; 391:601-5.
Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D. A novel




Marchetti A, Buttita F, Girlando S, Dalla Palma P, Pellegrini S, Fina P, Doglioni C,
Bevilacqua G, Barbareschi M. mdm2 gene alterations and mdm2 protein expression in
breast carcinomas. J Pathol 1995a; 175:31-8.
Marchetti A, Buttitta F, Pellegrini S, Merlo G, Chella A, Angeletti A, Bevilacqua G.
mdm2 gene amplification and overexpression in non-small cell lung carcinomas with
accumulation of the p53 protein in the absence of p53 gene mutations. Diagn Mol
Pathol 1995b; 4:93-7.
McBride OW, Merry D, Givol D. The gene for human p53 cellular tumour antigen is
located on chromosome 17 short arm (17p13). Proc Natl Acad Sci USA 1986; 83:130-
4. 
McCann AH, Kirley A, Carney DN, Corbally N, Magee HM, Keating G, Dervan PA.
Amplification of the MDM2 gene in human breast cancer and its association with
MDM2 and p53 protein status. Br J Cancer 1995; 71:981-5.
Meng RD, Phillips P, El-Deiry WS. p53-independent increase in E2F-1 expression
enhances the cytotoxic effects of etoposide and of adriamycin. Int J Oncol 1999; 14:5-
14.
Millikan R, Hulka B,  Thor AD, Zhang Y, Edgerton S, Zhang X, Pei H, He M, Wold
L, Melton LJ. P53 mutations in bengin breast tissue. J Clin Oncol 1995; 13:2293-300.  
Milner J, Medcalf EA. Cotranslation of activated mutant p53 with wildtype drives the
wildtype p53 protein into the mutant conformation. Cell 1991; 65: 765-74.
Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of
the human bax gene. Cell 1995; 80:293-9.
Moberg K, Starz MA, Lees JA. E2F-4 switches from p130 to p107 and pRb in
response to cell cycle reentry. Mol Cell Biol 1996; 16:1436-49.
Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene
product forms a complex with the p53 protein and inhibits p53-mediated
transactivation. Cell 1992; 69:1237-45.
Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database.
Nucleic Acids Res 1998; 26:3453-9.
Mommers ECM, van Diest PJ, Leonhart AM, Meijer CJ, Baak JPA. Expression of
proliferation and apoptosis-related proteins in usual ductal hyperplasia of the breast.




Montenarh M. Biochemical, immunological, and functional aspects of the growth-
suppressor/oncoprotein p53. Crit Rev Oncol 1992; 3:233-56.
Moreno A, Lloveras B, Figueras A, Escobedo A, Ramon JM, Sierra A, Fabra A.
Ductal carcinoma in situ of the breast: correlation between histologic classifications
and biologic markers. Mod Pathol 1997; 10:1088-92.
Moyret C, Theillet C, Laurent-Puig P, Moles J, Thomas G, Hamelin R. Relative
efficiency of denaturing gradient gel electrophoresis and single strand conformation
polymorphism in the detection of mutations in exons 5 to 8 of the p53 gene.
Oncogene 1994; 9:1739-43.
Mulligan LM, Matlashewski GJ, Scrable HJ, Cavenee WK. Mechanisms of p53 loss
in human sarcomas. Proc Natl Acad Sci USA 1990; 87:5863-7.
Munn KE, Walker PA, Menasce L, Varley JM. Mutation of the TP53 gene and allelic
imbalance at chromosome 17p13 in ductal carcinoma in situ. Br J Cancer 1996;
74:1578-85.
National Co-ordinating Group for Breast Screening Pathology: Pathology reporting in
breast cancer screening. 2nd edition. NHSBSP Publ, Sheffield, 1995.
Nelson WG, Kastan MB. The DNA template alterations that trigger p53-dependent
DNA response pathways. Mol Cell Biol 1994; 14:1815-23.
Neuman E, Sellers WR, McNeil JA, Lawrence JB, Kaelin WG Jr. Structure and
partial genomic sequence of the human E2F-1 gene. Gene 1996; 173:163-9.
Nicholson SA, Okby NT, Khan MA, Welsh JA, McMenamin MG, Travis WD, Jett
JR, Tazelaar HD, TrastekV, Pairolero PC, Corn PG, Herman JG, Liotta LA, Caporaso
NE, Harris CC. Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-
mediated apoptotic pathways in non-small cell lung carcinoma. Cancer Res 2001;
61:5636-43.
Nigro JM, Baker SJ, Preisinger AC, Jessup MJ, Hostetter R, Cleary K, Bigner SH,
Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris
CC, Vogelstein B. Mutations in the p53 gene occur in diverse human tumour types.
Nature 1989; 342:705-8.
Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the
cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;
368:753-6.
Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a




Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B.
Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature
1993; 362:857-60.
Oren M, Maltzman W, Levine AJ. Post-translational regulation of the 54k cellular
antigen in normal and transformed cells. Mol Cell Biol 1981; 1:101-10.
Osborne RJ, Merlo GR, Mitsudomi T, Venesio T, Liscia DS, Cappa APM, Chiba I,
Takahashi T, Nau NM, Callahan R, Minna JD. Mutations in the p53 gene in primary
human breast cancers. Cancer Res 1991; 51: 6194-8.
Ostrowski JL, Sawan A, Henry L, Wright C, Henry JA, Hennesy C, Lennard JW,
Angus B, Horne HW. p53 expression in human breast cancer related to survival and
prognostic factors: an immunohistochemical study. J Pathol 1991; 164:75-81.
Page DL, Anderson TJ. In: Page D, Anderson TJ (eds). Diagnostic histopathology of
the breast. New York: Churchill Livingstone, 1987: 193.
Page DL, Rogers LW. Carcinoma in situ (CIS). In: Page D, Anderson TJ (eds).
Diagnostic histopathology of the breast. New York: Churchill Livingstone, 1987: 157-
192.
Patchefsky AS, Schwartz GF, Finkelstein SD, Prestipino A, Sohn SE, Singer JS, Feig
SA . Heterogeneity of intraductal carcinoma of the breast. Cancer 1989; 63:731-41.
Penault-Llorca F, Adelaïde J, Houvenaeghel G, Hassoun J, Birnbaum D, Jacquemier
J. Optimization of immunohistochemical detection of ERBB2 in human breast cancer:
impact of fixation. J Pathol 1994;173:65-75.
Phillips AC, Bates S, Ryan KM, Helin K, Vousden KH. Induction of DNA synthesis
and apoptosis are separable functions of E2F-1. Genes Dev 1997; 11:1853-63.
Pierce AM, Fisher SM, Conti CJ, Johnson DG. Deregulated expression of E2F1
induces hyperplasia and co-operates with ras in skin tumour development. Oncogene
1998; 16:1267-76.
Pietilainen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma V, Syrjanem K.
Expression of p53 protein has no independent prognostic value in breast cancer. J
Pathol 1995; 177:225-32.
Poller DN, Roberts EC, Bell JA, Elston CW, Blamey RW, Ellie IO. p53 protein
expression in mammary ductal carcinoma in situ: relationship to





Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, Potes J,
Chen K, Orlow I, Lee H-W, Cordón-Cardó C, DePinho RA. The INK4a tumor
suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s
inhibition of p53. Cell 1998; 92:713-23.
Press MF, Hung G, Godolphin GW, Slamon DJ. Sensitivity of HER-2/neu antibodies
in archival tissue samples: potential source of error in immunohistochemical studies
of oncogene expression. Cancer Res 1994;54:2771-7.
Prosser J, Thompson AM, Cranston G, Evans HJ. Evidence that p53 behaves as a
tumour suppressor gene in sporadic breast tumours. Oncogene 1990; 5:1573-9.
Qian W, Hu LF, Chen F, Wang Y, Magnusson KP, Kashuba E, Klein G, Wiman KG.
Infrequent MDM2 gene amplification and absence of gross WAF1 gene alterations in
nasopharyngeal carcinoma. Eur J Cancer B Oral Oncol 1995; 31:328-32.
Qin X-Q, Livingston DM, Kaelin WG Jr, Adams P. Deregulated transcription factor
E2F-1 expression leads to S phase entry and p53-mediated apoptosis. Proc Natl Acad
Sci USA 1994; 91:10918-22.
Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a
tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle
arrest. Cell 1995; 83:993-1000.
Quelle DE, Cheng M, Ashmun RA, Sherr CJ. Cancer-associated mutations at the
INK4a locus cancel cell cycle arrest by 16INK4a but not by the alternative reading
frame protein p19ARF. Proc Natl Acad Sci USA 1997; 94:669-73.
Querzoli P, Albonico G, Ferretti S, Rinaldi R, Beccati D, Corcione S, Indelli M,
Nenci I. Modulation of biomarkers in minimal breast carcinoma: a model for human
breast carcinoma progression. Cancer 1998; 83:89-97.
Rabbani F, richon VM, Orlow I, Lu M-L, Drobnjak M, Dudas M, Charytonowicz E,
Dalbagni G, Cordon-Cardo C. Prognostic significance of transcription factor E2F-1 in
bladder cancer: genotypic and phenotypic characterization. J Natl Cancer Inst 1999;
91:874-1.
Raff T, van der Giet M, Endemann D, Wiederholt T, Paul M. Design and testing of
beta-actin primers for RT-PCR that do not co-amplify processed peudogenes.
Biotechniques 1997; 23:456-60.
Rahko E, Blanco G, Soini Y, Bloigu R, Jukkola A. A mutant TP53 gene status is
associated with a poor prognosis and anthracycline-resistance in breast cancer




Rajan PB, Scott DJ, Perry RH, Griggith CDM. p53 protein expression in ductal
carcinoma in situ (DCIS) of the breast. Breast Cancer Res Treat 1997; 42:283-90.
Reich NC, Oren M, Levine AJ. Two distinct mechanisms regulate the levels of
cellular tumor antigen, p53. Mol Cell Biol 1983; 3:2143-50.
Reid AH, Tsai MM, Venzon DJ, Wright CF, Lack EE, O’Leary TJ. MDM2
amplifiction, P53 mutation, and accumulation of the P53 gene product in malignant
fibrous histiocytoma. Diagn Mol Pathol 1996; 5:65-73.
Robertson KD, Jones PA. The human ARF cell cycle regulatory gene promoter is a
CpG island which can be silenced by DNA methylation and down-regulated by wild-
type p53. Mol Cell Biol 1998; 18:6457-73.
Rogel A, Popliker M, Webb CG, Oren M. p53 cellular tumor antigen: analysis of
mRNA levels in normal adult tissues, embryos, and tumors. Mol Cell Biol 1985;
5:2851-5.
Rohan TE, Hartwick W, Miller AB, Kandel RA. Immunohistochemical detection of
c-erbB-2 and p53 in benign breast disease and breast cancer risk. J Natl Cancer Inst
1998; 90:1262-9.
Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. p53 in node-
negative breast carcinoma: an immunohistochemical study of epidemiologic risk
factors, histologic features, and prognosis. J Clin Oncol 1995; 13:821-30.
Rosai J. Breast: In situ carcinoma. In: Rosai J (ed). Ackerman’s Surgical Pathology,
8th edition. St Louis: Mosby, 1996; vol 2:1596-1601.
Roth J, Dobbelstein M, Freedman D, Shenk T, Levine AJ. Nucleo-cytoplasmic
shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a
pathway used by the human immunodeficiency virus rev protein. EMBO J 1998;
17:554-64.
Runnebaum IB, Nagarajan M, Bowman M, Soto D, Sukumar S. Mutations in p53 as
potential molecular markers for human breast cancer. Proc Natl Acad Sci USA 1991;
88: 10657-61.
Saito M, Helin K, Valentine MB, Griffith BB, William CL, Harlow E, Look AT.
Amplification of the E2F-1 transcription factor in the HEL erythroleukemia cell line.
Genomics 1995; 25:130-8.
Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual, 2nd




Sardet C, Vidal M, Cobrinik D, Geng Y, Onufryk C, Chen A Weinberg RA. E2F-4
and E2F-5, two novel members of the E2F family, are expressed in the early phases of
the cell cycle. Proc Natl Acad Sci USA 1995; 92:2403-7.
Sarnow P, Ho YS, Williams J, Levine AJ. Adenovirus E1B-58Kd tumor antigen and
SV40 large tumor antigen are physically associated with the same 54 Kd cellular
protein in transformed cells. Cell 1982; 28:387-94.
Seki A, Kodama J, Miyagi Y, Kamimura S, Yoshinouchi M, Kudo T. Amplification
of the mdm-2 gene and p53 abnormalities in uterine sarcomas. Int J Cancer 1997;
73:33-7.
Seow A, Duffy SW, McGee MA, Lee HP. Breast cancer in Singapore: trends in
incidence 1968-1992. Int J Epidemiol 1996; 25:40-5.
Shan B, Lee W-H. Deregulated expression of E2F-1 induces S phase entry and leads
to apoptosis. Mol Cell Biol 1994; 14:8166-73.
Shaulsky G, Goldfinger N, Tosky MS, Levine AJ, Rotter V. Nuclear localization is
essential for the activity of p53 protein. Oncogene 1991; 6:2055-65.
Sheikh MS, Shao ZM, Hussain A, Fontana JA. The p53-binding protein MDM2 gene
is differentially expressed in human breast carcinoma. Cancer Res 1993; 53:3226-8.
Sherr CJ. Cancer cell cycles. Science 1996; 274:1672-7.
Shibagaki I, Tanaka H, Shimada Y, Wagata T, Ikenaga M, Imamura M, Ishizaki K.
p53 mutation, murine double minute 2 amplification, and human papillomavirus
infection are frequently involved but not associated with each other in oesophageal
squamous cell carcinoma. Clin Cancer Res 1995; 1:769-73.
Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di
Fronzo G, Veronesi U. p53 as an independent prognostic marker in lymph node
negative breast cancer patients. J Natl Cancer Inst 1993; 85:965-70.
Silverstein MJ, Waisman JR, Gamagami P, Gierson ED, Colburn WJ, Rosser RJ,
Gordon PS, Lewinsky BS, Fingerhut A. Intraductal carcinoma of the breast (208
cases). Clinical factors influencing treatment choice. Cancer 1990; 66:102-8.
Silverstein MJ, Poller DN, Waisman LR, Colburn WJ, Barth A, Gierson ED,
Lewinsky B, Gamagami P, Slamon DJ. Prognostic classification of breast ductal
carcinoma in situ. Lancet 1995; 345:1154-7.
Singh P, Wong SH, Hong W. Overexpression of E2F-1 in rat embryo fibroblasts leads




Solin LJ, Yeh I-T, Kurtz J, Fourquet A, Recht A, Kuske R, McCormick B, Cross MA,
Schultz DJ, Amalric R. Ductal carcinoma in situ (intraductal carcinoma) of the breast
treated with breast-conserving surgery and definitive irradiation: correlation of
pathologic parameters with outcome of treatment. Cancer 1993; 71:2532-42.
Solin LJ, Kurtz J, Fourquet A, Amalric R, Recht A, Bornstein BA, Kuske R, Taylor
M, Barrett W, Fowble B, Haffty B, Schultz DJ, Yeh IT, McCormick B, McNeese M.
Fifteen-year results of breast-conserving surgery and definitive breast irradiation for
the treatment of ductal carcinoma in situ of the breast.
J Clin Oncol 1996;14:754-63.
Souza RF, Yin J, Smolinski N, Zou T-T, Wang S, Shi Y-Q, Rhyu M-G, Cottrell J,
Abraham JM, Biden K, Simms L, Leggett B, Bove S, Frank T, Powell SM, Sugimura
H, Young J, Harpaz N, Shimizu K, Matsubara N, Meltzer SJ. Frequent mutation of
the E2F-4 cell cycle gene in primary human gastrointestinal tumors. Cancer Res
1997;57:2350-3.
Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A.
Complex structure and regulation of the P16 (MST1) locus. Cancer Res 1995;
55:2988-94.
Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I,
Ryan K, Hara E, Vousden KH, Peters G. The alternative product from the human
CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and
MDM2. EMBO J 1998; 17:5001-14.
Soussi T, de Fromentel CC, May P. Structural aspects of the p53 protein in relation to
gene evolution. Oncogene 1990; 5:945-52.
Suzuki T, Yasui W, Yokozaki H, Naka K, Ishikawa T, Tahara E. Expression of the
E2F family in human gastrointestinal carcinomas. Int J Cancer 1999; 81:535-8.
Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M,
Pass H, Gazdar AF, Minna JD. p53: a frequent target for genetic abnormalities in lung
cancer. Science 1989; 246:491-4.
Tao W, Levine AJ. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for
Hdm2-mediated degradation of p53. Proc Natl Acad Sci USA 1999a; 96:3077-80.
Tao W, Levine AJ. P19(ARF) stabilises p53 by blocking nucleo-cytoplasmic shuttling
of Mdm2. Proc Natl Acad Sci USA 1999b; 96:6937-41.
The Consensus Conference Committee. Consensus conference on the classification of




Thor AD, Moore II DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus
JN, Schwartz L, Chen LC, Mayall BH. Accumulation of p53 tumor suppressor gene
protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst
1992; 84:845-55.
Trimarchi  JM, Fairchild B, Verona R, Moberg K, Andon N, Lee JA. E2F-6, a
member of the E2F family that can behave as a transcriptional repressor. Proc Natl
Acad Sci USA 1998; 95:2850-8.
Tsuda H, Fukutomi T, Hirohashi S. Pattern of gene alteration in intraductal breast
neoplasms associated with histological type and grade. Clin Cancer Res 1995; 1:261-
7.
Umekita Y, Takasaki T, Yoshida H. Expression of p53 protein in benign epithelial
hyperplasia, atypical ductal hyperplasia, non-invasive and invasive mammary
carcinoma: an immunohistochemical study. Virchows Archiv 1994a; 424:491-4.
Umekita Y, Kobayashi K, Saheki T, Yoshida H. Nuclear accumulation of p53 protein
correlates with mutations in the p53 gene on archival paraffin-embedded tissues of
human breast cancer. Jpn J Cancer Res 1994b; 85:825-30.
Valle VD, Duro D, Bernard O, Larsen CJ. The human protein p19ARF is not detected
in hemopoietic human cell lines that abundantly express the alternative β transcript of
the p16INK4a/MST1 gene. Oncogene 1997; 15:2475-81.
Van Diest PJ, van Dam P, Henzen-Longmans SC, Berns E, van der Burg MEL, Green
J, et al. A scoring system for immunohistochemical staining: consensus report of the
task force for basic research of the EORTC-GCCG. Clin Pathol 1997;50:801-4.
Van Zee KJ, Calvano JE, Bisogna M, Borgen PI. INK4a exon 1β is wildtype in MCF-
7. Proc AACR 1998; 39:441.
Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M,
Nakamura Y, White R, Smits AMM, Bos JL. Genetic alterations during colorectal
tumour development. New Engl J Med 1988; 319:525.
Walsh T, Chappell SA, Shaw JA, Rosemary AW. Microsatellite instability in ductal
carcinoma in situ of the breast. J Pathol 1998; 185:18-24.
Wang D, Russell JL, Johnson DG. E2F4 and E2F1 have similar proliferative
properties but different apoptotic and oncogenic properties in vivo. Mol Cell Biol
2000; 20:3417-24.
Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters




Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human
breast with special reference to possible precancerous lesions.  J Natl Cancer Instit
1975; 55:231-73.
Werness BA, Levine AJ, Howley PM. The E6 proteins encoded by human
paillomavirus type 16 and 18 can complex p53 in vitro. Science 1990; 248:76-9.
Willett WC, Rockhill B, Hankinson SE, Hunter DJ, Colditz GA. Epidemiology and
nongenetic causes of breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne
CK (eds). Diseases of the Breast, 2nd ed, Lippincott Williams & Wilkins,
Philadelphia, 2000: 179.
Wu X, Bayle H, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop.
Genes Dev 1993; 7:1126-32.
Wu X, Levine AJ. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci
USA 1994; 91:3602-6.
Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson N. Tumor induction
and tissue atrophy in mice lacking E2F-1. Cell 1996; 85:537-48.
Youngson BJ, Anelli A, Van Zee KJ, Borgen PI, Norton L, Rosen PP.
Microdissection and molecular genetic analysis of HER2/neu in breast carcinoma. Am
J Surg Pathol 1995; 19:1354-8.
Zafrani B, Leroyer A, Fourquet A, Laurent M, Trophilme D, Validire P, Sastre-Garau
X. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a
new classification. A study of 127 cases: correlation with estrogen and progesterone
receptors, p53 and c-erbB-2 proteins, and proliferative activity. Semin Diagn Pathol
1994; 11:208-14.
Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes
p53. ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression
pathways. Cell 1998; 92:725-34.
Zou M, Shi Y, al-Sedairy S, Hussain SS, Farid NR. The expression of the MDM2





AJCC/TNM STAGING SYSTEM FOR BREAST CARCINOMA
(Modified from AJCC Manual for Staging Cancer, 1992)
Definition of TNM
Primary Tumour (T)
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma in situ: intraductal carcinoma, lobular carcinoma in situ, or
Paget’s disease of the nipple with no tumour
T1 Tumour 2 cm or less in greatest dimension
T2 Tumour more than 2 cm but no more than 5 cm in greatest dimension
T3 Tumour more than 5 cm in greatest dimension
T4 Tumour of any size with direct extension to chest wall and/or skin, or
inflammatory carcinoma
Regional Lymph Nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis to movable ipsilateral axillary lymph node(s)
N2 Metastasis to ipsilateral axillary lymph node(s) fixed to one another or
to other structures
N3 Metastasis to ipsilateral internal mammary lymph node(s)
Distant Metastasis (M)
MX Presence of distant metastasis cannot be assessed
M0 No distant metastasis




Breast Cancer Stage Grouping
Stage 0 Tis N0 M0
Stage I T1 N0 M0
Stage IIA T0 N1 M0
T1 N1 M0
T2 N0 M0
Stage IIB T2 N1 M0
T3 N0 M0





Stage IIIB T4 Any N M0
Any T N3 M0
Stage IV Any T Any N M1
